Anabolic steroid(Redirected from Anabolic steroids)
Anabolic steroids, also known more properly as anabolic–androgenic steroids (AAS), are steroidal androgens that include natural androgens like testosterone as well as synthetic androgens that are structurally related and have similar effects to testosterone. They are anabolic and increase protein within cells, especially in skeletal muscles, and also have varying degrees of androgenic and virilizing effects, including induction of the development and maintenance of masculine secondary sexual characteristics such as the growth of facial and body hair. The word anabolic, referring to anabolism, comes from the Greek ἀναβολή anabole, "that which is thrown up, mound". Androgens or AAS are one of three types of sex hormone agonists, the others being estrogens like estradiol and progestogens like progesterone.
Chemical structure of the natural AAS testosterone (androst-4-en-17β-ol-3-one).
|Synonyms||Anabolic steroids; Androgens|
|Biological target||Androgen receptor|
|Chemical class||Steroids; Androstanes; Estranes|
AAS were synthesized in the 1930s, and are now used therapeutically in medicine to stimulate muscle growth and appetite, induce male puberty and treat chronic wasting conditions, such as cancer and AIDS. The American College of Sports Medicine acknowledges that AAS, in the presence of adequate diet, can contribute to increases in body weight, often as lean mass increases and that the gains in muscular strength achieved through high-intensity exercise and proper diet can be additionally increased by the use of AAS in some individuals.
Health risks can be produced by long-term use or excessive doses of AAS. These effects include harmful changes in cholesterol levels (increased low-density lipoprotein and decreased high-density lipoprotein), acne, high blood pressure, liver damage (mainly with most oral AAS), and dangerous changes in the structure of the left ventricle of the heart. Conditions pertaining to hormonal imbalances such as gynecomastia and testicular size reduction may also be caused by AAS. In women and children, AAS can cause irreversible masculinization.
Ergogenic uses for AAS in sports, racing, and bodybuilding as performance-enhancing drugs are controversial because of their adverse effects and the potential to gain unfair advantage in physical competitions. Their use is referred to as doping and banned by most major sporting bodies. For many years, AAS have been by far the most detected doping substances in IOC-accredited laboratories. In countries where AAS are controlled substances, there is often a black market in which smuggled, clandestinely manufactured or even counterfeit drugs are sold to users.
Since the discovery and synthesis of testosterone in the 1930s, AAS have been used by physicians for many purposes, with varying degrees of success. These can broadly be grouped into anabolic, androgenic, and other uses.
- Bone marrow stimulation: For decades, AAS were the mainstay of therapy for hypoplastic anemias due to leukemia, kidney failure or aplastic anemia.
- Growth stimulation: AAS can be used by pediatric endocrinologists to treat children with growth failure. However, the availability of synthetic growth hormone, which has fewer side effects, makes this a secondary treatment.
- Stimulation of appetite and preservation and increase of muscle mass: AAS have been given to people with chronic wasting conditions such as cancer and AIDS.
- Stimulation of lean body mass and prevention of bone loss in elderly men, as some studies indicate. However, a 2006 placebo-controlled trial of low-dose testosterone supplementation in elderly men with low levels of testosterone found no benefit on body composition, physical performance, insulin sensitivity, or quality of life.
- Prevention or treatment of osteoporosis in postmenopausal women. Nandrolone decanoate is approved for this use. Although they have been indicated for this indication, AAS saw very little use for this purpose due to their virilizing side effects.
- Aiding weight gain following surgery or physical trauma, during chronic infection, or in the context of unexplained weight loss.
- Counteracting the catabolic effect of long-term corticosteroid therapy.
- Oxandrolone improves both short-term and long-term outcomes in people recovering from severe burns and is well-established as a safe treatment for this indication.
- Treatment of idiopathic short stature, hereditary angioedema, alcoholic hepatitis, and hypogonadism.
- Methyltestosterone is used in the treatment of delayed puberty, hypogonadism, cryptorchidism, and erectile dysfunction in males, and in low doses to treat menopausal symptoms (specifically for osteoporosis, hot flashes, and to increase libido and energy), postpartum breast pain and engorgement, and breast cancer in women.
- Androgen replacement therapy for men with low levels of testosterone; also effective in improving libido for elderly males.
- Induction of male puberty: Androgens are given to many boys distressed about extreme delay of puberty. Testosterone is now nearly the only androgen used for this purpose and has been shown to increase height, weight, and fat-free mass in boys with delayed puberty.
- Masculinizing hormone therapy for transgender men, other transmasculine people, and intersex people, by producing masculine secondary sexual characteristics such as a voice deepening, increased bone and muscle mass, masculine fat distribution, facial and body hair, and clitoral enlargement, as well as mental changes such as alleviation of gender dysphoria and increased sex drive.
- Treatment of breast cancer in women, although they are now very rarely used for this purpose due to their marked virilizing side effects.
- In low doses as a component of hormone therapy for postmenopausal and transgender women, for instance to increase energy, well-being, libido, and quality of life, as well as to reduce hot flashes. Testosterone is usually used for this purpose, although methyltestosterone is also used.
- Male hormonal contraception; currently experimental, but potential for use as effective, safe, reliable, and reversible male contraceptives.
Most steroid users are not athletes. In the United States, between 1 million and 3 million people (1% of the population) are thought to have used AAS. Studies in the United States have shown that AAS users tend to be mostly middle-class heterosexual men with a median age of about 25 who are noncompetitive bodybuilders and non-athletes and use the drugs for cosmetic purposes. "Among 12- to 17-year-old boys, use of steroids and similar drugs jumped 25 percent from 1999 to 2000, with 20 percent saying they use them for looks rather than sports, a study by insurer Blue Cross Blue Shield found."(Eisenhauer) Another study found that non-medical use of AAS among college students was at or less than 1%. According to a recent survey, 78.4% of steroid users were noncompetitive bodybuilders and non-athletes, while about 13% reported unsafe injection practices such as reusing needles, sharing needles, and sharing multidose vials, though a 2007 study found that sharing of needles was extremely uncommon among individuals using AAS for non-medical purposes, less than 1%. Another 2007 study found that 74% of non-medical AAS users had post-secondary degrees and more had completed college and fewer had failed to complete high school than is expected from the general populace. The same study found that individuals using AAS for non-medical purposes had a higher employment rate and a higher household income than the general population. AAS users tend to research the drugs they are taking more than other controlled-substance users; however, the major sources consulted by steroid users include friends, non-medical handbooks, internet-based forums, blogs, and fitness magazines, which can provide questionable or inaccurate information.
AAS users tend to be unhappy with the portrayal of AAS as deadly in the media and in politics. According to one study, AAS users also distrust their physicians and in the sample 56% had not disclosed their AAS use to their physicians. Another 2007 study had similar findings, showing that, while 66% of individuals using AAS for non-medical purposes were willing to seek medical supervision for their steroid use, 58% lacked trust in their physicians, 92% felt that the medical community's knowledge of non-medical AAS use was lacking, and 99% felt that the public has an exaggerated view of the side-effects of AAS use. A recent study has also shown that long term AAS users were more likely to have symptoms of muscle dysmorphia and also showed stronger endorsement of more conventional male roles. A recent study in the Journal of Health Psychology showed that many users believed that steroids used in moderation were safe.
AAS have been used by men and women in many different kinds of professional sports to attain a competitive edge or to assist in recovery from injury. These sports include bodybuilding, weightlifting, shot put and other track and field, cycling, baseball, wrestling, mixed martial arts, boxing, football, and cricket. Such use is prohibited by the rules of the governing bodies of most sports. AAS use occurs among adolescents, especially by those participating in competitive sports. It has been suggested that the prevalence of use among high-school students in the U.S. may be as high as 2.7%. Male students used AAS more frequently than female students and, on average, those that participated in sports used steroids more often than those that did not.
The AAS that have been used most commonly in medicine are testosterone and its many esters (but most typically testosterone undecanoate, testosterone enanthate, testosterone cypionate, and testosterone propionate), nandrolone esters (typically nandrolone decanoate and nandrolone phenylpropionate), stanozolol, and metandienone (methandrostenolone). Others that have also been available and used commonly but to a lesser extent include methyltestosterone, oxandrolone, mesterolone, and oxymetholone, as well as drostanolone propionate (dromostanolone propionate), metenolone (methylandrostenolone) esters (specifically metenolone acetate and metenolone enanthate), and fluoxymesterone. Dihydrotestosterone (DHT), known as androstanolone or stanolone when used medically, and its esters are also notable, although they are not widely used in medicine. Boldenone undecylenate and trenbolone acetate are used in veterinary medicine.
Designer steroids are AAS that have not been approved and marketed for medical use but have been distributed through the black market. Examples of notable designer steroids include 1-testosterone (dihydroboldenone), methasterone, trenbolone enanthate, desoxymethyltestosterone, tetrahydrogestrinone, and methylstenbolone.
|Generic name||Class||Brand name(s)||Route(s)||Launch||Status||Hitsa|
|Boldenone undecylenate||T; Ester||Equipoise, Parenabol||IM||1960s||Veterinaryb||544,000|
|Drostanolone propionate||DHT; Ester||Masteron||IM||1961||Discontinued||574,000|
|Ethylestrenol||19-NT; Alkyl||Maxibolin, Orabolin||Oral||1961||Availableb||117,000|
|Fluoxymesterone||T; Alkyl||Halotestin, Ultandren||Oral||1957||Availableb||478,000|
|Mestanolone||DHT; Alkyl||Androstalone, Ermalone||Oral||1950s||Discontinued||278,000|
|Metandienone||T; Alkyl||Dianabol||Oral, IM||1958||Availableb||996,000|
|Metenolone acetate||DHT; Ester||Primobolan||Oral||1961||Availableb||224,000|
|Metenolone enanthate||DHT; Ester||Primobolan Depot||IM||1962||Availableb||371,000|
|Nandrolone decanoate||19-NT; Ester||Deca-Durabolin||IM||1962||Available||926,000|
|Nandrolone phenylpropionate||19-NT; Ester||Durabolin||IM||1959||Availableb||395,000|
|Norethandrolone||19-NT; Alkyl||Nilevar, Pronabol||Oral||1956||Availableb||124,000|
|Oxandrolone||DHT; Alkyl||Oxandrin, Anavar||Oral||1964||Availableb||1,280,000|
|Oxymetholone||DHT; Alkyl||Anadrol, Anapolon||Oral||1961||Availableb||902,000|
|Prasterone (DHEA)||T; Prohormone||Numerous||Many||1970s||Available||11,600,000|
|Stanozolol||DHT; Alkyl||Winstrol, Stromba||Oral, IM||1962||Discontinued||1,790,000|
|Testosterone cypionate||T; Ester||Depo-Testosterone||IM||1951||Available||1,290,000|
|Testosterone enanthate||T; Ester||Delatestryl||IM||1954||Available||1,210,000|
|Testosterone propionate||T; Ester||Testoviron||IM||1937||Available||1,010,000|
|Testosterone undecanoate||T; Ester||Aveed, Andriol, Nebido||Oral, IM||1970s||Available||385,000|
|Trenbolone acetate||19-NT; Ester||Finajet, Finaject||IM||1970s||Veterinary||651,000|
|Footnotes: a = Hits = Google Search hits (as of December 2017). b = Availability limited / mostly discontinued. Class: T = Testosterone. DHT = Dihydrotestosterone. 19-NT = 19-Nortestosterone (nandrolone). Alkyl = 17α-Alkylated. Sources: See individual articles.|
Routes of administrationEdit
There are four common forms in which AAS are administered: oral pills; injectable steroids; creams/gels for topical application; and skin patches. Oral administration is the most convenient. Testosterone administered by mouth is rapidly absorbed, but it is largely converted to inactive metabolites, and only about one-sixth is available in active form. In order to be sufficiently active when given by mouth, testosterone derivatives are alkylated at the 17α position, e.g. methyltestosterone and fluoxymesterone. This modification reduces the liver's ability to break down these compounds before they reach the systemic circulation.
Testosterone can be administered parenterally, but it has more irregular prolonged absorption time and greater activity in muscle in enanthate, undecanoate, or cypionate ester form. These derivatives are hydrolyzed to release free testosterone at the site of injection; absorption rate (and thus injection schedule) varies among different esters, but medical injections are normally done anywhere between semi-weekly to once every 12 weeks. A more frequent schedule may be desirable in order to maintain a more constant level of hormone in the system. Injectable steroids are typically administered into the muscle, not into the vein, to avoid sudden changes in the amount of the drug in the bloodstream. In addition, because estered testosterone is dissolved in oil, intravenous injection has the potential to cause a dangerous embolism (clot) in the bloodstream.
Transdermal patches (adhesive patches placed on the skin) may also be used to deliver a steady dose through the skin and into the bloodstream. Testosterone-containing creams and gels that are applied daily to the skin are also available, but absorption is inefficient (roughly 10%, varying between individuals) and these treatments tend to be more expensive. Individuals who are especially physically active and/or bathe often may not be good candidates, since the medication can be washed off and may take up to six hours to be fully absorbed. There is also the risk that an intimate partner or child may come in contact with the application site and inadvertently dose himself or herself; children and women are highly sensitive to testosterone and can suffer unintended masculinization and health effects, even from small doses. Injection is the most common method used by individuals administering AAS for non-medical purposes.
The traditional routes of administration do not have differential effects on the efficacy of the drug. Studies indicate that the anabolic properties of AAS are relatively similar despite the differences in pharmacokinetic principles such as first-pass metabolism. However, the orally available forms of AAS may cause liver damage in high doses.
- Dermatological/integumental: oily skin, acne vulgaris, acne conglobata, seborrhea, stretch marks (due to rapid muscle enlargement), hypertrichosis (excessive body hair growth), androgenic alopecia (pattern hair loss; scalp baldness), fluid retention/edema.
- Reproductive/endocrine: libido changes, reversible infertility, hypogonadotropic hypogonadism.
- Male-specific: spontaneous erections, nocturnal emissions, priapism, erectile dysfunction, gynecomastia (mostly only with aromatizable and hence estrogenic AAS), oligospermia/azoospermia, testicular atrophy, intratesticular leiomyosarcoma, prostate hypertrophy, prostate cancer.
- Female-specific: masculinization, irreversible voice deepening, hirsutism (excessive facial/body hair growth), menstrual disturbances (e.g., anovulation, oligomenorrhea, amenorrhea, dysmenorrhea), clitoral enlargement, breast atrophy, uterine atrophy, teratogenicity (in female fetuses).
- Child-specific: premature epiphyseal closure and associated short stature, precocious puberty in boys, delayed puberty and contrasexual precocity in girls.
- Psychiatric/neurological: mood swings, irritability, aggression, violent behavior, impulsivity/recklessness, hypomania/mania, euphoria, depression, anxiety, dysphoria, suicidality, delusions, psychosis, withdrawal, dependence, neurotoxicity, cognitive impairment.
- Musculoskeletal: muscle hypertrophy, muscle strains, tendon ruptures, rhabdomyolysis.
- Cardiovascular: dyslipidemia (e.g., increased LDL levels, decreased HDL levels, reduced apo-A1 levels), atherosclerosis, hypertension, left ventricular hypertrophy, cardiomyopathy, myocardial hypertrophy, polycythemia/erythrocytosis, arrhythmias, thrombosis (e.g., embolism, stroke), myocardial infarction, sudden death.
- Hepatic: elevated liver function tests (AST, ALT, bilirubin, LDH, ALP), hepatotoxicity, jaundice, hepatic steatosis, hepatocellular adenoma, hepatocellular carcinoma, cholestasis, peliosis hepatis; all mostly or exclusively with 17α-alkylated AAS.
- Renal: renal hypertrophy, nephropathy, acute renal failure (secondary to rhabdomyolysis), focal segmental glomerulosclerosis, renal cell carcinoma.
- Others: glucose intolerance, insulin resistance, immune dysfunction.
Depending on the length of drug use, there is a chance that the immune system can be damaged. Most of these side-effects are dose-dependent, the most common being elevated blood pressure, especially in those with pre-existing hypertension. In addition to morphological changes of the heart which may have a permanent adverse effect on cardiovascular efficiency.
AAS have been shown to alter fasting blood sugar and glucose tolerance tests. AAS such as testosterone also increase the risk of cardiovascular disease or coronary artery disease. Acne is fairly common among AAS users, mostly due to stimulation of the sebaceous glands by increased testosterone levels. Conversion of testosterone to DHT can accelerate the rate of premature baldness for males genetically predisposed, but testosterone itself can produce baldness in females.
A number of severe side effects can occur if adolescents use AAS. For example, AAS may prematurely stop the lengthening of bones (premature epiphyseal fusion through increased levels of estrogen metabolites), resulting in stunted growth. Other effects include, but are not limited to, accelerated bone maturation, increased frequency and duration of erections, and premature sexual development. AAS use in adolescence is also correlated with poorer attitudes related to health.
Other side-effects can include alterations in the structure of the heart, such as enlargement and thickening of the left ventricle, which impairs its contraction and relaxation, and therefore reducing ejected blood volume. Possible effects of these alterations in the heart are hypertension, cardiac arrhythmias, congestive heart failure, heart attacks, and sudden cardiac death. These changes are also seen in non-drug-using athletes, but steroid use may accelerate this process. However, both the connection between changes in the structure of the left ventricle and decreased cardiac function, as well as the connection to steroid use have been disputed.
AAS use can cause harmful changes in cholesterol levels: Some steroids cause an increase in LDL "bad" cholesterol and a decrease in HDL "good" cholesterol. In addition, steroids provoke a rapid increase in body weight and an accompanying rise in blood pressure, both of which leave users more vulnerable to a cardiovascular event.
AAS use in adolescents quickens bone maturation and may reduce adult height in high doses. Low doses of AAS such as oxandrolone are used in the treatment of idiopathic short stature, but this may only quicken maturation rather than increasing adult height.
There are also sex-specific side effects of AAS. Development of breast tissue in males, a condition called gynecomastia (which is usually caused by high levels of circulating estradiol), may arise because of increased conversion of testosterone to estradiol by the enzyme aromatase. Reduced sexual function and temporary infertility can also occur in males. Another male-specific side-effect that can occur is testicular atrophy, caused by the suppression of natural testosterone levels, which inhibits production of sperm (most of the mass of the testes is developing sperm). This side-effect is temporary; the size of the testicles usually returns to normal within a few weeks of discontinuing AAS use as normal production of sperm resumes.
Female-specific side effects include increases in body hair, permanent deepening of the voice, enlarged clitoris, and temporary decreases in menstrual cycles. Alteration of fertility and ovarian cysts can also occur in females. When taken during pregnancy, AAS can affect fetal development by causing the development of male features in the female fetus and female features in the male fetus.
Kidney tests revealed that nine of the ten steroid users developed a condition called focal segmental glomerulosclerosis, a type of scarring within the kidneys. The kidney damage in the bodybuilders has similarities to that seen in morbidly obese patients, but appears to be even more severe.
A 2005 review in CNS Drugs determined that "significant psychiatric symptoms including aggression and violence, mania, and less frequently psychosis and suicide have been associated with steroid abuse. Long-term steroid abusers may develop symptoms of dependence and withdrawal on discontinuation of AAS". High concentrations of AAS, comparable to those likely sustained by many recreational AAS users, produce apoptotic effects on neurons, raising the specter of possibly irreversible neurotoxicity. Recreational AAS use appears to be associated with a range of potentially prolonged psychiatric effects, including dependence syndromes, mood disorders, and progression to other forms of substance abuse, but the prevalence and severity of these various effects remains poorly understood. There is no evidence that steroid dependence develops from therapeutic use of AAS to treat medical disorders, but instances of AAS dependence have been reported among weightlifters and bodybuilders who chronically administered supraphysiologic doses. Mood disturbances (e.g. depression, [hypo-]mania, psychotic features) are likely to be dose- and drug-dependent, but AAS dependence or withdrawal effects seem to occur only in a small number of AAS users.
Large-scale long-term studies of psychiatric effects on AAS users are not currently available. In 2003, the first naturalistic long-term study on ten users, seven of which having completed the study, found a high incidence of mood disorders and substance abuse, but few clinically relevant changes in physiological parameters or laboratory measures were noted throughout the study, and these changes were not clearly related to periods of reported AAS use. A 13-month study, which was published in 2006 and which involved 320 body builders and athletes suggests that the wide range of psychiatric side-effects induced by the use of AAS is correlated to the severity of abuse.
Diagnostic Statistical Manual assertionEdit
DSM-IV lists General diagnostic criteria for a personality disorder guideline that "The pattern must not be better accounted for as a manifestation of another mental disorder, or to the direct physiological effects of a substance (e.g. drug or medication) or a general medical condition (e.g. head trauma).". As a result, AAS users may get misdiagnosed by a psychiatrist not told about their habit.
Cooper, Noakes, Dunne, Lambert, and Rochford identified that AAS-using individuals are more likely to score higher on borderline (4.7 times), antisocial (3.8 times), paranoid (3.4 times), schizotypal (3.1 times), histrionic (2.9 times), passive-aggressive (2.4 times), and narcissistic (1.6 times) personality profiles than non-users. Other studies have suggested that antisocial personality disorder is slightly more likely among AAS users than among non-users (Pope & Katz, 1994). Bipolar dysfunction, substance dependency, and conduct disorder have also been associated with AAS use.
Mood and anxietyEdit
Affective disorders have long been recognised as a complication of AAS use. Case reports describe both hypomania and mania, along with irritability, elation, recklessness, racing thoughts and feelings of power and invincibility that did not meet the criteria for mania/hypomania. Of 53 bodybuilders who used AAS, 27 (51%) reported unspecified mood disturbance.
Aggression and hypomaniaEdit
From the mid-1980s onward, the media reported "roid rage" as a side effect of AAS.:23
A 2005 review determined that some, but not all, randomized controlled studies have found that AAS use correlates with hypomania and increased aggressiveness, but pointed out that attempts to determine whether AAS use triggers violent behavior have failed, primarily because of high rates of non-participation. A 2008 study on a nationally representative sample of young adult males in the United States found an association between lifetime and past-year self-reported AAS use and involvement in violent acts. Compared with individuals that did not use steroids, young adult males that used AAS reported greater involvement in violent behaviors even after controlling for the effects of key demographic variables, previous violent behavior, and polydrug use. A 1996 review examining the blind studies available at that time also found that these had demonstrated a link between aggression and steroid use, but pointed out that with estimates of over one million past or current steroid users in the United States at that time, an extremely small percentage of those using steroids appear to have experienced mental disturbance severe enough to result in clinical treatments or medical case reports.
A 1996 randomized controlled trial, which involved 43 men, did not find an increase in the occurrence of angry behavior during 10 weeks of administration of testosterone enanthate at 600 mg/week, but this study screened out subjects that had previously abused steroids or had any psychiatric antecedents. A trial conducted in 2000 using testosterone cypionate at 600 mg/week found that treatment significantly increased manic scores on the YMRS, and aggressive responses on several scales. The drug response was highly variable. However: 84% of subjects exhibited minimal psychiatric effects, 12% became mildly hypomanic, and 4% (2 subjects) became markedly hypomanic. The mechanism of these variable reactions could not be explained by demographic, psychological, laboratory, or physiological measures.
A 2006 study of two pairs of identical twins, in which one twin used AAS and the other did not, found that in both cases the steroid-using twin exhibited high levels of aggressiveness, hostility, anxiety, and paranoid ideation not found in the "control" twin. A small-scale study of 10 AAS users found that cluster B personality disorders were confounding factors for aggression.
The relationship between AAS use and depression is inconclusive. There have been anecdotal reports of depression and suicide in teenage steroid users, but little systematic evidence. A 1992 review found that AAS may both relieve and cause depression, and that cessation or diminished use of AAS may also result in depression, but called for additional studies due to disparate data. In the case of suicide, 3.9% of a sample of 77 those classified as AAS users reported attempting suicide during withdrawal (Malone, Dimeff, Lombardo, & Sample, 1995).
Androgens such as testosterone, androstenedione and dihydrotestosterone are required for the development of organs in the male reproductive system, including the seminal vesicles, epididymis, vas deferens, penis and prostate. AAS are testosterone derivatives designed to maximize the anabolic effects of testosterone. AAS are consumed by elite athletes competing in sports like weightlifting, bodybuilding, and track and field. Male recreational athletes take AAS to achieve an “enhanced” physical appearance.
AAS consumption disrupts the hypothalamic–pituitary–gonadal axis (HPG axis) in males. In the HPG axis, gonadotropin-releasing hormone (GnRH) is secreted from the arcuate nucleus of the hypothalamus and stimulates the anterior pituitary to secrete the two gonadotropins, follicle stimulating hormone (FSH) and luteinizing hormone (LH). In adult males, LH stimulates the Leydig cells in the testes to produce testosterone which is required to form new sperm through spermatogenesis. AAS consumption leads to dose-dependent suppression of gonadotropin release through suppression of GnRH from the hypothalamus (long-loop mechanism) or from direct negative feedback on the anterior pituitary to inhibit gonadotropin release (short-loop mechanism), leading to AAS-induced hypogonadism.
Mechanism of actionEdit
The pharmacodynamics of AAS are unlike peptide hormones. Water-soluble peptide hormones cannot penetrate the fatty cell membrane and only indirectly affect the nucleus of target cells through their interaction with the cell’s surface receptors. However, as fat-soluble hormones, AAS are membrane-permeable and influence the nucleus of cells by direct action. The pharmacodynamic action of AAS begin when the exogenous hormone penetrates the membrane of the target cell and binds to an androgen receptor (AR) located in the cytoplasm of that cell. From there, the compound hormone-receptor diffuses into the nucleus, where it either alters the expression of genes or activates processes that send signals to other parts of the cell. Different types of AAS bind to the AAR with different affinities, depending on their chemical structure. Some AAS such as metandienone bind weakly to this receptor in vitro, but still exhibit AR-mediated effects in vivo. The reason for this discrepancy is not known.
The effect of AAS on muscle mass is caused in at least two ways: first, they increase the production of proteins; second, they reduce recovery time by blocking the effects of stress hormone cortisol on muscle tissue, so that catabolism of muscle is greatly reduced. It has been hypothesized that this reduction in muscle breakdown may occur through AAS inhibiting the action of other steroid hormones called glucocorticoids that promote the breakdown of muscles. AAS also affect the number of cells that develop into fat-storage cells, by favouring cellular differentiation into muscle cells instead. AAS can also decrease fat by increasing basal metabolic rate (BMR), since an increase in muscle mass increases BMR.
Anabolic and androgenic effectsEdit
As their name suggests, AAS have two different, but overlapping, types of effects: anabolic, meaning that they promote anabolism (cell growth), and androgenic (or virilizing), meaning that they affect the development and maintenance of masculine characteristics.
Some examples of the anabolic effects of these hormones are increased protein synthesis from amino acids, increased appetite, increased bone remodeling and growth, and stimulation of bone marrow, which increases the production of red blood cells. Through a number of mechanisms AAS stimulate the formation of muscle cells and hence cause an increase in the size of skeletal muscles, leading to increased strength.
The androgenic effects of AAS are numerous. Depending on the length of use, the side effects of the steroid can be irreversible. Processes affected include pubertal growth, sebaceous gland oil production, and sexuality (especially in fetal development). Some examples of virilizing effects are growth of the clitoris in females and the penis in male children (the adult penis size does not change due to steroids[medical citation needed] ), increased vocal cord size, increased libido, suppression of natural sex hormones, and impaired production of sperm. Effects on women include deepening of the voice, facial hair growth, and possibly a decrease in breast size. Men may develop an enlargement of breast tissue, known as gynecomastia, testicular atrophy, and a reduced sperm count.
The androgenic:anabolic ratio of an AAS is an important factor when determining the clinical application of these compounds. Compounds with a high ratio of androgenic to an anabolic effects are the drug of choice in androgen-replacement therapy (e.g., treating hypogonadism in males), whereas compounds with a reduced androgenic:anabolic ratio are preferred for anemia and osteoporosis, and to reverse protein loss following trauma, surgery, or prolonged immobilization. Determination of androgenic:anabolic ratio is typically performed in animal studies, which has led to the marketing of some compounds claimed to have anabolic activity with weak androgenic effects. This disassociation is less marked in humans, where all AAS have significant androgenic effects.
A commonly used protocol for determining the androgenic:anabolic ratio, dating back to the 1950s, uses the relative weights of ventral prostate (VP) and levator ani muscle (LA) of male rats. The VP weight is an indicator of the androgenic effect, while the LA weight is an indicator of the anabolic effect. Two or more batches of rats are castrated and given no treatment and respectively some AAS of interest. The LA/VP ratio for an AAS is calculated as the ratio of LA/VP weight gains produced by the treatment with that compound using castrated but untreated rats as baseline: (LAc,t–LAc)/(VPc,t–VPc). The LA/VP weight gain ratio from rat experiments is not unitary for testosterone (typically 0.3–0.4), but it is normalized for presentation purposes, and used as basis of comparison for other AAS, which have their androgenic:anabolic ratios scaled accordingly (as shown in the table above). In the early 2000s, this procedure was standardized and generalized throughout OECD in what is now known as the Hershberger assay.
Body composition and strength improvementsEdit
Body weight in men may increase by 2 to 5 kg as a result of short-term (<10 weeks) AAS use, which may be attributed mainly to an increase of lean mass. Animal studies also found that fat mass was reduced, but most studies in humans failed to elucidate significant fat mass decrements. The effects on lean body mass have been shown to be dose-dependent. Both muscle hypertrophy and the formation of new muscle fibers have been observed. The hydration of lean mass remains unaffected by AAS use, although small increments of blood volume cannot be ruled out.
The upper region of the body (thorax, neck, shoulders, and upper arm) seems to be more susceptible for AAS than other body regions because of predominance of ARs in the upper body. The largest difference in muscle fiber size between AAS users and non-users was observed in type I muscle fibers of the vastus lateralis and the trapezius muscle as a result of long-term AAS self-administration. After drug withdrawal, the effects fade away slowly, but may persist for more than 6–12 weeks after cessation of AAS use.
Strength improvements in the range of 5 to 20% of baseline strength, depending largely on the drugs and dose used as well as the administration period. Overall, the exercise where the most significant improvements were observed is the bench press. For almost two decades, it was assumed that AAS exerted significant effects only in experienced strength athletes. A randomized controlled trial demonstrated, however, that even in novice athletes a 10-week strength training program accompanied by testosterone enanthate at 600 mg/week may improve strength more than training alone does. This dose is sufficient to significantly improve lean muscle mass relative to placebo even in subjects that did not exercise at all. The anabolic effects of testosterone enanthate were highly dose dependent.
Dissociation of effectsEdit
Endogenous/natural AAS like testosterone and DHT and synthetic AAS mediate their effects by binding to and activating the AR. On the basis of animal bioassays, the effects of these agents have been divided into two partially dissociable types: anabolic (myotrophic) and androgenic. Dissociation between the ratios of these two types of effects is observed in rat bioassays with various AAS relative to the ratio observed with testosterone. Explanations for the dissociation include differences in intracellular metabolism, functional selectivity (recruitment of coactivators), and non-genomic mechanisms (i.e., signaling through non-AR membrane androgen receptors, or mARs). Support for the latter two explanations is limited and more hypothetical, but there is a good deal of support for the intracellular metabolism explanation.
The measurement of the dissociation between anabolic and androgenic effects among AAS is based largely on a simple although arguably unsophisticated and outdated model involving rat tissue bioassays. It is referred to as the myotrophic–androgenic index. In this model, anabolic (myotrophic) activity is measured by change in the weight of the rat bulbocavernosus/levator ani muscle and androgenic activity is measured by change in the weight of the rat ventral prostate (or, alternatively, the rat seminal vesicles) in response to exposure to the AAS, and the measurements are then compared and used to form a ratio.
Testosterone is metabolized in various tissues by 5α-reductase into DHT, which is 3- to 10-fold more potent as an AR agonist, and by aromatase into estradiol, which is an estrogen and lacks significant AR affinity. In addition, DHT is metabolized by 3α-hydroxysteroid dehydrogenase (3α-HSD) and 3β-hydroxysteroid dehydrogenase (3β-HSD) into 3α-androstanediol and 3β-androstanediol, respectively, which are metabolites with little or no AR affinity. 5α-Reductase is widely distributed throughout the body, and is concentrated to various extents in skin (particularly the scalp, beard-area of the face, pubic area, and genital area (penis and scrotum)), prostate, seminal vesicles, liver, and the brain. In contrast, expression of 5α-reductase in skeletal muscle is undetectable. Aromatase is highly expressed in adipose tissue and the brain, and is also expressed significantly in skeletal muscle. 3α-HSD is also highly expressed in skeletal muscle.
Natural AAS like testosterone and DHT and synthetic AAS are analogues and are very similar structurally. For this reason, they have the capacity to bind to and be metabolized by the same steroid-metabolizing enzymes. According to the intracellular metabolism explanation, the androgenic-to-anabolic ratio of a given AR agonist is related to its capacity to be transformed by the aforementioned enzymes in conjunction with the AR activity of any resulting products. For instance, whereas the AR activity of testosterone is greatly potentiated by local conversion via 5α-reductase into DHT in tissues where 5α-reductase is expressed, an AAS that is not metabolized by 5α-reductase or is already 5α-reduced, such as DHT itself or a derivative (like mesterolone or drostanolone), would not undergo such potentiation in said tissues. Moreover, nandrolone is metabolized by 5α-reductase, but unlike the case of testosterone and DHT, the 5α-reduced metabolite of nandrolone has much lower affinity for the AR than does nandrolone itself, and this results in reduced AR activation in 5α-reductase-expressing tissues. As so-called "androgenic" tissues such as skin/hair follicles and male reproductive tissues are very high in 5α-reductase expression, while skeletal muscle is virtually devoid of 5α-reductase, this may primarily explain the high myotrophic–androgenic ratio and dissociation seen with nandrolone, as well as with various other AAS.
Aside from 5α-reductase, aromatase may inactivate testosterone signaling in skeletal muscle and adipose tissue, so AAS that lack aromatase affinity, in addition to being free of the potential side effect of gynecomastia, might be expected to have a higher myotrophic–androgenic ratio in comparison. In addition, DHT is inactivated by high activity of 3α-HSD in skeletal muscle (and cardiac tissue), and AAS that lack affinity for 3α-HSD could similarly be expected to have a higher myotrophic–androgenic ratio (although perhaps also increased long-term cardiovascular risks). In accordance, DHT, mestanolone (17α-methyl-DHT), and mesterolone (1α-methyl-DHT) are all described as very poorly anabolic due to inactivation by 3α-HSD in skeletal muscle, whereas other DHT derivatives with other structural features like metenolone, oxandrolone, oxymetholone, drostanolone, and stanozolol are all poor substrates for 3α-HSD and are described as potent anabolics.
The intracellular metabolism theory explains how and why remarkable dissociation between anabolic and androgenic effects might occur despite the fact that these effects are mediated through the same signaling receptor, and of course why dissociation is invariably incomplete. In support of the model is the rare condition congenital 5α-reductase type 2 deficiency, in which the 5α-reductase type 2 enzyme is defective, production of DHT is impaired, and DHT levels are low while testosterone levels are normal. Males with this condition are born with ambiguous genitalia and a severely underdeveloped or even absent prostate gland. In addition, at the time of puberty, such males develop normal musculature, voice deepening, and libido, but have reduced facial hair, a female pattern of body hair (i.e., largely restricted to the pubic triangle and underarms), no incidence of male pattern hair loss, and no prostate enlargement or incidence of prostate cancer. They also notably do not develop gynecomastia as a consequence of their condition.
|Compound||rAR (%)||hAR (%)|
|Abbreviations: rAR = Rat prostate androgen receptor at 4°C. hAR = Intact human MCF-7 breast cancer androgen receptor at 37°C. Sources: |
An animal study found that two different kinds of androgen response elements could differentially respond to testosterone and DHT upon activation of the AR. Whether this is involved in the differences in the ratios of anabolic-to-myotrophic effect of different AAS is unknown however.
Testosterone signals not only through the nuclear AR, but also through mARs, including ZIP9 and GPRC6A. It has been proposed that differential signaling through mARs may be involved in the dissociation of the anabolic and androgenic effects of AAS. Indeed, DHT has less than 1% of the affinity of testosterone for ZIP9, and the synthetic AAS metribolone and mibolerone are ineffective competitors for the receptor similarly, indicating that AAS do show differential interactions with the AR and mARs. However, women with complete androgen insensitivity syndrome (CAIS), who have a male genotype (46,XY) and testes but a defect in the AR such that it is non-functional (and hence are completely insensitive to the AR-mediated effects of androgens like testosterone), show a perfectly female phenotype despite having testosterone levels in the high end of the normal male range. In addition, these women have little or no sebum production, incidence of acne, or body hair growth (including in the pubic and axillary areas). Moreover, CAIS women have lean body mass that is normal for females but is of course greatly reduced for males. These observations suggest that the AR is mainly or exclusively responsible for masculinization and myotrophy caused by androgens. In any case, the mARs have been found to be involved in some other effects of testosterone like modulation of prostate cancer risk and progression.
Changes in endogenous testosterone levels may also contribute to differences in myotrophic–androgenic ratio between testosterone and synthetic AAS. AR agonists are antigonadotropic – that is, they dose-dependently suppress gonadal testosterone production and hence reduce systemic testosterone concentrations. By suppressing endogenous testosterone levels and effectively replacing AR signaling in the body with that of the exogenous AAS, the myotrophic–androgenic ratio of a given AAS may be further, dose-dependently increased, and this hence may be an additional factor contributing to the differences in myotrophic–androgenic ratio among different AAS. In addition, some AAS, such as 19-nortestosterone derivatives like nandrolone, are also potent progestogens, and activation of the progesterone receptor (PR) is antigonadotropic similarly to activation of the AR. The combination of sufficient AR and PR activation can suppress circulating testosterone levels into the castrate range in men (i.e., complete suppression of gonadal testosterone production and circulating testosterone levels decreased by about 95%). As such, combined progestogenic activity may serve to further increase the myotrophic–androgenic ratio for a given AAS.
GABAA receptor modulationEdit
Some AAS, such as testosterone, DHT, stanozolol, and methyltestosterone, have been found to modulate the GABAA receptor similarly to endogenous neurosteroids like allopregnanolone, 3α-androstanediol, dehydroepiandrosterone sulfate, and pregnenolone sulfate. It has been suggested that this may contribute as an alternative or additional mechanism to the neurological and behavioral effects of AAS.
Comparison of AASEdit
AAS differ in a variety of ways including in their capacities to be metabolized by steroidogenic enzymes such as 5α-reductase, 3-hydroxysteroid dehydrogenases, and aromatase, in whether their potency as AR agonists is potentiated or diminished by 5α-reduction, in their ratios of anabolic/myotrophic to androgenic effect, in their estrogenic, progestogenic, and neurosteroid activities, in their oral activity, and in their capacity to produce hepatotoxicity.
|Ethylestrenol||19-NT; 17α-A||+ (↓)||±||–||***||+||+||+||+|
|Fluoxymesterone||T; 17α-A||+ (↑)||–||–||*||–||–||+||+|
|Methyltestosterone||T; 17α-A||+ (↑)||+||–||*||+||–||+||+|
|Norethandrolone||19-NT; 17α-A||+ (↓)||±||–||***||+||+||+||+|
|Key: + = Yes. ± = Low. – = No. ↑ = Potentiated. ↓ = Inactivated. *** = High. ** = Moderate. * = Low. Abbreviations: 5α-R = Metabolized by 5α-reductase. AROM = Metabolized by aromatase. 3-HSD = Metabolized by 3α- and/or 3β-HSD. AAR = Anabolic-to-androgenic ratio (amount of anabolic (myotrophic) effect relative to androgenic effect). Estr = Estrogenic. Prog = Progestogenic. Oral = Oral activity. Hepat = Hepatotoxicity. Footnotes: a = As testosterone undecanoate. Sources: |
|Notes: Values are percentages (%). Reference ligands (100%) were progesterone for the PR, testosterone for the AR, estradiol for the ER, dexamethasone for the GR, aldosterone for the MR, dihydrotestosterone for SHBG, and cortisol for CBG. Footnotes: a = 1-hour incubation time (4 hours is standard for this assay; may affect affinity value). Sources: |
|Route||Anabolic activity by||Androgenic
|Dissociation index by|
|Nitr. ratio||Myotrophy||Nitr. ratio||Myotrophy|
|Notes: All assays done with rodents, unless noted otherwise. Footnotes: a = Monkeys. Sources: |
5α-Reductase and androgenicityEdit
Testosterone can be robustly converted by 5α-reductase into DHT in so-called androgenic tissues such as skin, scalp, prostate, and seminal vesicles, but not in muscle or bone, where 5α-reductase either is not expressed or is only minimally expressed. As DHT is 3- to 10-fold more potent as an agonist of the AR than is testosterone, the AR agonist activity of testosterone is thus markedly and selectively potentiated in such tissues. In contrast to testosterone, DHT and other 4,5α-dihydrogenated AAS are already 5α-reduced, and for this reason, cannot be potentiated in androgenic tissues. 19-Nortestosterone derivatives like nandrolone can be metabolized by 5α-reductase similarly to testosterone, but 5α-reduced metabolites of 19-nortestosterone derivatives (e.g., 5α-dihydronandrolone) tend to have reduced activity as AR agonists, resulting in reduced androgenic activity in tissues that express 5α-reductase. In addition, some 19-nortestosterone derivatives, including trestolone (7α-methyl-19-nortestosterone (MENT)), 11β-methyl-19-nortestosterone (11β-MNT), and dimethandrolone (7α,11β-dimethyl-19-nortestosterone), cannot be 5α-reduced. Conversely, certain 17α-alkylated AAS like methyltestosterone are 5α-reduced and potentiated in androgenic tissues similarly to testosterone. 17α-Alkylated DHT derivatives cannot be potentiated via 5α-reductase however, as they are already 4,5α-reduced.
The capacity to be metabolized by 5α-reductase and the AR activity of the resultant metabolites appears to be one of the major, if not the most important determinant of the androgenic–myotrophic ratio for a given AAS. AAS that are not potentiated by 5α-reductase or that are weakened by 5α-reductase in androgenic tissues have a reduced risk of androgenic side effects such as acne, androgenic alopecia (male-pattern baldness), hirsutism (excessive male-pattern hair growth), benign prostatic hyperplasia (prostate enlargement), and prostate cancer, while incidence and magnitude of other effects such as muscle hypertrophy, bone changes, voice deepening, and changes in sex drive show no difference.
Aromatase and estrogenicityEdit
Testosterone can be metabolized by aromatase into estradiol, and many other AAS can be metabolized into their corresponding estrogenic metabolites as well. As an example, the 17α-alkylated AAS methyltestosterone and metandienone are converted by aromatase into methylestradiol. 4,5α-Dihydrogenated derivatives of testosterone such as DHT cannot be aromatized, whereas 19-nortestosterone derivatives like nandrolone can be but to a greatly reduced extent. Some 19-nortestosterone derivatives, such as dimethandrolone and 11β-MNT, cannot be aromatized due to steric hindrance provided by their 11β-methyl group, whereas the closely related AAS trestolone (7α-methyl-19-nortestosterone), in relation to its lack of an 11β-methyl group, can be aromatized. AAS that are 17α-alkylated (and not also 4,5α-reduced or 19-demethylated) are also aromatized but to a lesser extent than is testosterone. However, it is notable that estrogens that are 17α-substituted (e.g., ethinylestradiol and methylestradiol) are of markedly increased estrogenic potency due to improved metabolic stability, and for this reason, 17α-alkylated AAS can actually have high estrogenicity and comparatively greater estrogenic effects than testosterone.
The major effect of estrogenicity is gynecomastia (woman-like breasts). AAS that have a high potential for aromatization like testosterone and particularly methyltestosterone show a high risk of gynecomastia at sufficiently high dosages, while AAS that have a reduced potential for aromatization like nandrolone show a much lower risk (though still potentially significant at high dosages). In contrast, AAS that are 4,5α-reduced, and some other AAS (e.g., 11β-methylated 19-nortestosterone derivatives), have no risk of gynecomastia. In addition to gynecomastia, AAS with high estrogenicity have increased antigonadotropic activity, which results in increased potency in suppression of the hypothalamic-pituitary-gonadal axis and gonadal testosterone production.
Many 19-nortestosterone derivatives, including nandrolone, trenbolone, ethylestrenol (ethylnandrol), metribolone (R-1881), trestolone, 11β-MNT, dimethandrolone, and others, are potent agonists of the progesterone receptor (AR) and hence are progestogens in addition to AAS. Similarly to the case of estrogenic activity, the progestogenic activity of these drugs serves to augment their antigonadotropic activity. This results in increased potency and effectiveness of these AAS as antispermatogenic agents and male contraceptives (or, put in another way, increased potency and effectiveness in producing azoospermia and reversible male infertility).
Oral activity and hepatotoxicityEdit
Non-17α-alkylated testosterone derivatives such as testosterone itself, DHT, and nandrolone all have poor oral bioavailability due to extensive first-pass hepatic metabolism and hence are not orally active. A notable exception to this are AAS that are androgen precursors or prohormones, including dehydroepiandrosterone (DHEA), androstenediol, androstenedione, boldione (androstadienedione), bolandiol (norandrostenediol), bolandione (norandrostenedione), dienedione, mentabolan (MENT dione, trestione), and methoxydienone (methoxygonadiene) (although these are relatively weak AAS). AAS that are not orally active are used almost exclusively in the form of esters administered by intramuscular injection, which act as depots and function as long-acting prodrugs. Examples include testosterone, as testosterone cypionate, testosterone enanthate, and testosterone propionate, and nandrolone, as nandrolone phenylpropionate and nandrolone decanoate, among many others (see here for a full list of testosterone and nandrolone esters). An exception is the very long-chain ester testosterone undecanoate, which is orally active, albeit with only very low oral bioavailability (approximately 3%). In contrast to most other AAS, 17α-alkylated testosterone derivatives show resistance to metabolism due to steric hindrance and are orally active, though they may be esterified and administered via intramuscular injection as well.
In addition to oral activity, 17α-alkylation also confers a high potential for hepatotoxicity, and all 17α-alkylated AAS have been associated, albeit uncommonly and only after prolonged use (different estimates between 1 and 17%), with hepatotoxicity. In contrast, testosterone esters have only extremely rarely or never been associated with hepatotoxicity, and other non-17α-alkylated AAS only rarely, although long-term use may reportedly still increase the risk of hepatic changes (but at a much lower rate than 17α-alkylated AAS and reportedly not at replacement dosages).[additional citation(s) needed] In accordance, D-ring glucuronides of testosterone and DHT have been found to be cholestatic.
Aside from prohormones and testosterone undecanoate, almost all orally active AAS are 17α-alkylated. A few AAS that are not 17α-alkylated are orally active. Some examples include the testosterone 17-ethers cloxotestosterone, quinbolone, and silandrone, which are prodrugs (to testosterone, boldenone (Δ1-testosterone), and testosterone, respectively), the DHT 17-ethers mepitiostane, mesabolone, and prostanozol (which are also prodrugs), the 1-methylated DHT derivatives mesterolone and metenolone (although these are relatively weak AAS), and the 19-nortestosterone derivatives dimethandrolone and 11β-MNT, which have improved resistance to first-pass hepatic metabolism due to their 11β-methyl groups (in contrast to them, the related AAS trestolone (7α-methyl-19-nortestosterone) is not orally active). As these AAS are not 17α-alkylated, they show minimal potential for hepatotoxicity.
DHT, via its metabolite 3α-androstanediol (produced by 3α-hydroxysteroid dehydrogenase (3α-HSD)), is a neurosteroid that acts via positive allosteric modulation of the GABAA receptor. Testosterone, via conversion into DHT, also produces 3α-androstanediol as a metabolite and hence has similar activity. Some AAS that are or can be 5α-reduced, including testosterone, DHT, stanozolol, and methyltestosterone, among many others, can or may modulate the GABAA receptor, and this may contribute as an alternative or additional mechanism to their central nervous system effects in terms of mood, anxiety, aggression, and sex drive.
- 17α-Alkylation: methyltestosterone, metandienone, fluoxymesterone, oxandrolone, oxymetholone, stanozolol, norethandrolone, ethylestrenol
- 19-Demethylation: nandrolone, trenbolone, norethandrolone, ethylestrenol, trestolone, dimethandrolone
- 5α-Reduction: androstanolone, drostanolone, mestanolone, mesterolone, metenolone, oxandrolone, oxymetholone, stanozolol
- 3β- and/or 17β-esterification: testosterone enanthate, nandrolone decanoate, drostanolone propionate, boldenone undecylenate, trenbolone acetate
As well as others such as 1-dehydrogenation (e.g., metandienone, boldenone), 1-substitution (e.g., mesterolone, metenolone), 2-substitution (e.g., drostanolone, oxymetholone, stanozolol), 4-substitution (e.g., clostebol, oxabolone), and various other modifications.
|Position||Moiety||Type||Length (in C)||Rank||Group|
|Testosterone propionate||C17β||Propanoic acid||Straight-chain fatty acid||3||5||Short|
|Testosterone cypionate||C17β||Cyclopentylpropanoic acid||Aromatic fatty acid||–||4||Moderate|
|Testosterone enanthate||C17β||Heptanoic acid||Straight-chain fatty acid||7||3||Moderate|
|Testosterone undecanoate||C17β||Undecanoic acid||Straight-chain fatty acid||11||2||Long|
|Testosterone buciclate||C17β||Bucyclic acid||Aromatic carboxylic acid||–||1||Long|
|Position||Moiety||Type||Length (in C)|
|Boldenone undecylenate||C17β||Undecylenic acid||Straight-chain fatty acid||11||Long|
|Drostanolone propionate||C17β||Propanoic acid||Straight-chain fatty acid||3||Short|
|Metenolone acetate||C17β||Ethanoic acid||Straight-chain fatty acid||2||Short|
|Metenolone enanthate||C17β||Heptanoic acid||Straight-chain fatty acid||7||Long|
|Nandrolone decanoate||C17β||Decanoic acid||Straight-chain fatty acid||10||Long|
|Nandrolone phenylpropionate||C17β||Phenylpropanoic acid||Aromatic fatty acid||–||Long|
|Trenbolone acetate||C17β||Ethanoic acid||Straight-chain fatty acid||2||Short|
|Trenbolone enanthate||C17β||Heptanoic acid||Straight-chain fatty acid||7||Long|
Detection in body fluidsEdit
The most commonly employed human physiological specimen for detecting AAS usage is urine, although both blood and hair have been investigated for this purpose. The AAS, whether of endogenous or exogenous origin, are subject to extensive hepatic biotransformation by a variety of enzymatic pathways. The primary urinary metabolites may be detectable for up to 30 days after the last use, depending on the specific agent, dose and route of administration. A number of the drugs have common metabolic pathways, and their excretion profiles may overlap those of the endogenous steroids, making interpretation of testing results a very significant challenge to the analytical chemist. Methods for detection of the substances or their excretion products in urine specimens usually involve gas chromatography–mass spectrometry or liquid chromatography-mass spectrometry.
Discovery of androgensEdit
The use of gonadal steroids pre-dates their identification and isolation. Medical use of testicle extract began in the late 19th century while its effects on strength were still being studied. The isolation of gonadal steroids can be traced back to 1931, when Adolf Butenandt, a chemist in Marburg, purified 15 milligrams of the male hormone androstenone from tens of thousands of litres of urine. This steroid was subsequently synthesized in 1934 by Leopold Ružička, a chemist in Zurich.
In the 1930s, it was already known that the testes contain a more powerful androgen than androstenone, and three groups of scientists, funded by competing pharmaceutical companies in the Netherlands, Germany, and Switzerland, raced to isolate it. This hormone was first identified by Karoly Gyula David, E. Dingemanse, J. Freud and Ernst Laqueur in a May 1935 paper "On Crystalline Male Hormone from Testicles (Testosterone)." They named the hormone testosterone, from the stems of testicle and sterol, and the suffix of ketone. The chemical synthesis of testosterone was achieved in August that year, when Butenandt and G. Hanisch published a paper describing "A Method for Preparing Testosterone from Cholesterol." Only a week later, the third group, Ruzicka and A. Wettstein, announced a patent application in a paper "On the Artificial Preparation of the Testicular Hormone Testosterone (Androsten-3-one-17-ol)." Ruzicka and Butenandt were offered the 1939 Nobel Prize in Chemistry for their work, but the Nazi government forced Butenandt to decline the honor, although he accepted the prize after the end of World War II.
Clinical trials on humans, involving either oral doses of methyltestosterone or injections of testosterone propionate, began as early as 1937. Testosterone propionate is mentioned in a letter to the editor of Strength and Health magazine in 1938; this is the earliest known reference to an AAS in a U.S. weightlifting or bodybuilding magazine. There are often reported rumors that German soldiers were administered AAS during the Second World War, the aim being to increase their aggression and stamina, but these are, as yet, unproven.:6 Adolf Hitler himself, according to his physician, was injected with testosterone derivatives to treat various ailments. AAS were used in experiments conducted by the Nazis on concentration camp inmates, and later by the allies attempting to treat the malnourished victims that survived Nazi camps.:6 President John F. Kennedy was administered steroids both before and during his presidency.
Development of synthetic AASEdit
The development of muscle-building properties of testosterone was pursued in the 1940s, in the Soviet Union and in Eastern Bloc countries such as East Germany, where steroid programs were used to enhance the performance of Olympic and other amateur weight lifters. In response to the success of Russian weightlifters, the U.S. Olympic Team physician John Ziegler worked with synthetic chemists to develop an AAS with reduced androgenic effects. Ziegler's work resulted in the production of methandrostenolone, which Ciba Pharmaceuticals marketed as Dianabol. The new steroid was approved for use in the U.S. by the Food and Drug Administration (FDA) in 1958. It was most commonly administered to burn victims and the elderly. The drug's off-label users were mostly bodybuilders and weight lifters. Although Ziegler prescribed only small doses to athletes, he soon discovered that those having abused Dianabol suffered from enlarged prostates and atrophied testes. AAS were placed on the list of banned substances of the IOC in 1976, and a decade later the committee introduced 'out-of-competition' doping tests because many athletes used AAS in their training period rather than during competition.
Three major ideas governed modifications of testosterone into a multitude of AAS: Alkylation at C17α position with methyl or ethyl group created orally active compounds because it slows the degradation of the drug by the liver; esterification of testosterone and nortestosterone at the C17β position allows the substance to be administered parenterally and increases the duration of effectiveness because agents soluble in oily liquids may be present in the body for several months; and alterations of the ring structure were applied for both oral and parenteral agents to seeking to obtain different anabolic-to-androgenic effect ratios.
Society and cultureEdit
Androgens were discovered in the 1930s and were characterized as having effects described as androgenic (i.e., virilizing) and anabolic (e.g., myotrophic, renotrophic). The term anabolic steroid can be dated as far back as at least the mid-1940s, when it was used to describe the at-the-time hypothetical concept of a testosterone-derived steroid with anabolic effects but with minimal or no androgenic effects. This concept was formulated based on the observation that steroids had ratios of renotrophic to androgenic potency that differed significantly, which suggested that anabolic and androgenic effects might be dissociable.
In 1953, a testosterone-derived steroid known as norethandrolone (17α-ethyl-19-nortestosterone) was synthesized at G. D. Searle & Company and was studied as a progestin, but was not marketed. Subsequently, in 1955, it was re-examined for testosterone-like activity in animals and was found to have similar anabolic activity to testosterone, but only one-sixteenth of its androgenic potency. It was the first steroid with a marked and favorable separation of anabolic and androgenic effect to be discovered, and has accordingly been described as the "first anabolic steroid". Norethandrolone was introduced for medical use in 1956, and was quickly followed by numerous similar steroids, for instance nandrolone phenylpropionate in 1959 and stanozolol in 1962. With these developments, anabolic steroid became the preferred term to refer to such steroids (over "androgen"), and entered widespread use.
Although anabolic steroid was originally intended to specifically describe testosterone-derived steroids with a marked dissociation of anabolic and androgenic effect, it is applied today indiscriminately to all steroids with AR agonism-based anabolic effects regardless of their androgenic potency, including even non-synthetic steroids like testosterone. While many anabolic steroids have diminished androgenic potency in comparison to anabolic potency, there is no anabolic steroid that is exclusively anabolic, and hence all anabolic steroids retain at least some degree of androgenicity. (Likewise, all "androgens" are inherently anabolic.) Indeed, it is probably not possible to fully dissociate anabolic effects from androgenic effects, as both types of effects are mediated by the same signaling receptor, the AR. As such, the distinction between the terms anabolic steroid and androgen is questionable, and this is the basis for the revised and more recent term anabolic–androgenic steroid (AAS).
The legal status of AAS varies from country to country: some have stricter controls on their use or prescription than others though in many countries they are not illegal. In the U.S., AAS are currently listed as Schedule III controlled substances under the Controlled Substances Act, which makes simple possession of such substances without a prescription a federal crime punishable by up to one year in prison for the first offense. Unlawful distribution or possession with intent to distribute AAS as a first offense is punished by up to ten years in prison. In Canada, AAS and their derivatives are part of the Controlled Drugs and Substances Act and are Schedule IV substances, meaning that it is illegal to obtain or sell them without a prescription; however, possession is not punishable, a consequence reserved for schedule I, II, or III substances. Those guilty of buying or selling AAS in Canada can be imprisoned for up to 18 months. Import and export also carry similar penalties.
In Canada, researchers have concluded that steroid use among student athletes is extremely widespread. A study conducted in 1993 by the Canadian Centre for Drug-Free Sport found that nearly 83,000 Canadians between the ages of 11 and 18 use steroids. AAS are also illegal without prescription in Australia, Argentina, Brazil and Portugal, and are listed as Class C Controlled Drugs in the United Kingdom. AAS are readily available without a prescription in some countries such as Mexico and Thailand.
The history of the U.S. legislation on AAS goes back to the late 1980s, when the U.S. Congress considered placing AAS under the Controlled Substances Act following the controversy over Ben Johnson's victory at the 1988 Summer Olympics in Seoul. AAS were added to Schedule III of the Controlled Substances Act in the Anabolic Steroids Control Act of 1990.
The same act also introduced more stringent controls with higher criminal penalties for offenses involving the illegal distribution of AAS and human growth hormone. By the early 1990s, after AAS were scheduled in the U.S., several pharmaceutical companies stopped manufacturing or marketing the products in the U.S., including Ciba, Searle, Syntex, and others. In the Controlled Substances Act, AAS are defined to be any drug or hormonal substance chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) that promote muscle growth. The act was amended by the Anabolic Steroid Control Act of 2004, which added prohormones to the list of controlled substances, with effect from January 20, 2005.
In the United Kingdom, AAS are classified as class C drugs for their illegal abuse potential, which puts them in the same class as benzodiazepines. AAS are in Schedule 4, which is divided in 2 parts; Part 1 contains most of the benzodiazepines and Part 2 contains the AAS.
Part 1 drugs are subject to full import and export controls with possession being an offence without an appropriate prescription. There is no restriction on the possession when it is part of a medicinal product. Part 2 drugs require a Home Office licence for importation and export unless the substance is in the form of a medicinal product and is for self-administration by a person.
Status in sportsEdit
AAS are banned by all major sports bodies including Association of Tennis Professionals, Major League Baseball, Fédération Internationale de Football Association the Olympics, the National Basketball Association, the National Hockey League, World Wrestling Entertainment and the National Football League. The World Anti-Doping Agency (WADA) maintains the list of performance-enhancing substances used by many major sports bodies and includes all anabolic agents, which includes all AAS and precursors as well as all hormones and related substances. Spain has passed an anti-doping law creating a national anti-doping agency. Italy passed a law in 2000 where penalties range up to three years in prison if an athlete has tested positive for banned substances. In 2006, Russian President Vladimir Putin signed into law ratification of the International Convention Against Doping in Sport which would encourage cooperation with WADA. Many other countries have similar legislation prohibiting AAS in sports including Denmark, France, the Netherlands and Sweden.
United States federal law enforcement officials have expressed concern about AAS use by police officers. "It's a big problem, and from the number of cases, it's something we shouldn't ignore. It's not that we set out to target cops, but when we're in the middle of an active investigation into steroids, there have been quite a few cases that have led back to police officers," says Lawrence Payne, a spokesman for the United States Drug Enforcement Administration. The FBI Law Enforcement Bulletin stated that “Anabolic steroid abuse by police officers is a serious problem that merits greater awareness by departments across the country". It is also believed that police officers across the United Kingdom "are using criminals to buy steroids" which he claims to be a top risk factor for police corruption.
Following the murder-suicide of Chris Benoit in 2007, the Oversight and Government Reform Committee investigated steroid usage in the wrestling industry. The Committee investigated WWE and Total Nonstop Action Wrestling (TNA), asking for documentation of their companies' drug policies. WWE CEO and Chairman, Linda and Vince McMahon respectively, both testified. The documents stated that 75 wrestlers—roughly 40 percent—had tested positive for drug use since 2006, most commonly for steroids.
AAS are frequently produced in pharmaceutical laboratories, but, in nations where stricter laws are present, they are also produced in small home-made underground laboratories, usually from raw substances imported from abroad. In these countries, the majority of steroids are obtained illegally through black market trade. These steroids are usually manufactured in other countries, and therefore must be smuggled across international borders. As with most significant smuggling operations, organized crime is involved.
In the late 2000s, the worldwide trade in illicit AAS increased significantly, and authorities announced record captures on three continents. In 2006, Finnish authorities announced a record seizure of 11.8 million AAS tablets. A year later, the DEA seized 11.4 million units of AAS in the largest U.S seizure ever. In the first three months of 2008, Australian customs reported a record 300 seizures of AAS shipments.
In the U.S., Canada, and Europe, illegal steroids are sometimes purchased just as any other illegal drug, through dealers who are able to obtain the drugs from a number of sources. Illegal AAS are sometimes sold at gyms and competitions, and through the mail, but may also be obtained through pharmacists, veterinarians, and physicians. In addition, a significant number of counterfeit products are sold as AAS, in particular via mail order from websites posing as overseas pharmacies. In the U.S., black-market importation continues from Mexico, Thailand, and other countries where steroids are more easily available, as they are legal.
AAS, alone and in combination with progestogens, have been studied as potential male hormonal contraceptives. Dual AAS and progestins such as trestolone and dimethandrolone undecanoate have also been studied as male contraceptives, with the latter under active investigation as of 2018.
Topical androgens have been used and studied in the treatment of cellulite in women. Topical androstanolone on the abdomen has been found to significantly decrease subcutaneous abdominal fat in women, and hence may be useful for improving body silhouette. However, men and hyperandrogenic women have higher amounts of abdominal fat than healthy women, and androgens have been found to increase abdominal fat in postmenopausal women and transgender men as well.
- Kicman, A T (2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–521. doi:10.1038/bjp.2008.165. PMC 2439524. PMID 18500378.
- Powers M (2011). Houglum J, Harrelson GL, eds. Performance-Enhancing Drugs. Principles of Pharmacology for Athletic Trainers (2nd ed.). SLACK Incorporated. p. 345. ISBN 978-1-55642-901-9.
- Barrett-Connor EL (1995). "Testosterone and risk factors for cardiovascular disease in men". Diabete Metab. 21 (3): 156–61. PMID 7556805.
- Yamamoto Y, Moore R, Hess HA, Guo GL, Gonzalez FJ, Korach KS, Maronpot RR, Negishi M (2006). "Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity". J Biol Chem. 281 (24): 16625–31. doi:10.1074/jbc.M602723200. PMID 16606610.
- De Piccoli B, Giada F, Benettin A, Sartori F, Piccolo E (1991). "Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function". Int J Sports Med. 12 (4): 408–12. doi:10.1055/s-2007-1024703. PMID 1917226.
- Turillazzi E, Perilli G, Di Paolo M, Neri M, Riezzo I, Fineschi V (2011). "Side effects of AAS abuse: an overview". Mini Rev Med Chem. 11 (5): 374–89. doi:10.2174/138955711795445925. PMID 21443513.
- Hartgens F, Kuipers H (2004). "Effects of androgenic-anabolic steroids in athletes". Sports Med. 34 (8): 513–54. doi:10.2165/00007256-200434080-00003. PMID 15248788.
- Kicman AT, Gower DB (July 2003). "Anabolic steroids in sport: biochemical, clinical and analytical perspectives". Ann. Clin. Biochem. 40 (Pt 4): 321–56. doi:10.1258/000456303766476977. PMID 12880534.
- Basaria S, Wahlstrom JT, Dobs AS (November 2001). "Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases". J. Clin. Endocrinol. Metab. 86 (11): 5108–17. doi:10.1210/jcem.86.11.7983. PMID 11701661.
- Ranke MB, Bierich JR (1986). "Treatment of growth hormone deficiency". Clinics in Endocrinology and Metabolism. 15 (3): 495–510. doi:10.1016/S0300-595X(86)80008-1. PMID 2429792.
- Grunfeld C, Kotler DP, Dobs A, Glesby M, Bhasin S (2006). "Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study". J. Acquir. Immune Defic. Syndr. 41 (3): 304–14. doi:10.1097/01.qai.0000197546.56131.40. PMID 16540931.
- Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R (1996). "Oxandrolone in AIDS-wasting myopathy". AIDS. 10 (14): 1657–62. doi:10.1097/00002030-199612000-00010. PMID 8970686.
- Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG (2001). "Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels". J. Gerontol. A Biol. Sci. Med. Sci. 56 (5): M266–72. doi:10.1093/gerona/56.5.M266. PMID 11320105.
- Baum NH, Crespi CA (2007). "Testosterone replacement in elderly men". Geriatrics. 62 (9): 14–8. PMID 17824721.
- Francis RM (2001). "Androgen replacement in aging men". Calcif. Tissue Int. 69 (4): 235–8. doi:10.1007/s00223-001-1051-9. PMID 11730258.
- Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ, Smith GE, Khosla S, Jensen MD (October 2006). "DHEA in elderly women and DHEA or testosterone in elderly men". N. Engl. J. Med. 355 (16): 1647–59. doi:10.1056/NEJMoa054629. PMID 17050889.
- Brent C Mangus; Michael G Miller (11 January 2005). Pharmacology Application in Athletic Training. F.A. Davis. pp. 151–. ISBN 978-0-8036-2027-8.
- Royal College of Physicians of London (1999). Osteoporosis: Clinical Guidelines for Prevention and Treatment. Royal College of Physicians. pp. 51–. ISBN 978-1-86016-079-0.
- Davis SR (1999). "The therapeutic use of androgens in women". J. Steroid Biochem. Mol. Biol. 69 (1–6): 177–84. doi:10.1016/s0960-0760(99)00054-0. PMID 10418991.
- William N. Taylor, M.D. (16 January 2002). Anabolic Steroids and the Athlete, 2d ed. McFarland. pp. 193–. ISBN 978-0-7864-1128-3.
- "Oxandrolone Tablets, USP - Rx only" (PDF). Drugs@FDA. U.S. Food and Drug Administration. 1 December 2006. Retrieved 21 June 2016.
- "Oxandrin (oxandrolone tablets, USP)" (PDF). Drugs@FDA. BTG Pharmaceuticals, U.S. Food and Drug Administration. 21 April 2003. Retrieved 21 June 2016.
- Li H, Guo Y, Yang Z, Roy M, Guo Q (June 2016). "The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis". Burns. 42 (4): 717–27. doi:10.1016/j.burns.2015.08.023. PMID 26454425.
- Rojas Y, Finnerty CC, Radhakrishnan RS, Herndon DN (December 2012). "Burns: an update on current pharmacotherapy". Expert Opinion on Pharmacotherapy. 13 (17): 2485–94. doi:10.1517/14656566.2012.738195. PMC 3576016. PMID 23121414.
- Bork K (August 2012). "Current management options for hereditary angioedema". Current Allergy and Asthma Reports. 12 (4): 273–80. doi:10.1007/s11882-012-0273-4. PMID 22729959.
- Choi G, Runyon BA (May 2012). "Alcoholic hepatitis: a clinician's guide". Clinics in Liver Disease. 16 (2): 371–85. doi:10.1016/j.cld.2012.03.015. PMID 22541704.
- Manuchair Ebadi (31 October 2007). Desk Reference of Clinical Pharmacology, Second Edition. CRC Press. pp. 434–. ISBN 978-1-4200-4744-8.
- John A. Yagiela; Frank J. Dowd; Bart Johnson; Angelo Mariotti, Enid A. Neidle (19 March 2010). Pharmacology and Therapeutics for Dentistry - E-Book. Elsevier Health Sciences. pp. 569–. ISBN 0-323-07824-9.
- Shah K, Montoya C, Persons RK (April 2007). "Clinical inquiries. Do testosterone injections increase libido for elderly hypogonadal patients?". J Fam Pract. 56 (4): 301–3. PMID 17403329.
- Yassin AA, Saad F (March 2007). "Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only". J Sex Med. 4 (2): 497–501. doi:10.1111/j.1743-6109.2007.00442.x. PMID 17367445.
- Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA (December 1997). "Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men". Clin. Endocrinol. 47 (6): 727–37. doi:10.1046/j.1365-2265.1997.3071113.x. PMID 9497881.
- Nieschlag E, Büchter D, Von Eckardstein S, Abshagen K, Simoni M, Behre HM (December 1999). "Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men". Clin. Endocrinol. 51 (6): 757–63. doi:10.1046/j.1365-2265.1999.00881.x. PMID 10619981.
- Arslanian S, Suprasongsin C (1997). "Testosterone treatment in adolescents with delayed puberty: changes in body composition, protein, fat, and glucose metabolism". J. Clin. Endocrinol. Metab. 82 (10): 3213–20. doi:10.1210/jc.82.10.3213. PMID 9329341.
- Moore E, Wisniewski A, Dobs A (August 2003). "Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects". J. Clin. Endocrinol. Metab. 88 (8): 3467–73. doi:10.1210/jc.2002-021967. PMID 12915619.
- Ask a Gender Therapist: Can I Transition if I’m Non-Binary or Genderfluid? – Dara Hoffman-Fox. May 7, 2014. Retrieved November 17, 2014.
- Genderqueer, Pansexual, LGBTQ: Will Gender Exist 100 Years From Now? – Rebooted. October 24, 2013. Retrieved November 17, 2014.
- Young people exploring nonbinary gender roles – SF Gate. February 12, 2014. Retrieved November 17, 2014.
- Ask Matt: My Genderqueer Child Wants to Use Testosterone – Tranifesto. January 9, 2014. Retrieved November 17, 2014.
- Warne GL, Grover S, Zajac JD (2005). "Hormonal therapies for individuals with intersex conditions: protocol for use". Treatments in Endocrinology. 4 (1): 19–29. doi:10.2165/00024677-200504010-00003. PMID 15649098.
- What is Intersex – An Intersex FAQ by Inter/Act – Inter/Act Youth Archived 2014-12-07 at the Wayback Machine. September 12, 2014. Retrieved December 5, 2014.
- Michael C. Perry; Donald C. Doll; Carl E. Freter (30 July 2012). Perry's The Chemotherapy Source Book. Lippincott Williams & Wilkins. pp. 409–. ISBN 978-1-4698-0343-2.
- Allegra JC, Bertino J, Bonomi P, Byrne P, Carpenter J, Catalano R, Creech R, Dana B, Durivage H, Einhorn L (December 1985). "Metastatic breast cancer: preliminary results with oral hormonal therapy". Semin. Oncol. 12 (4 Suppl 6): 61–4. PMID 3909420.
- Bachmann GA (1999). "Androgen cotherapy in menopause: evolving benefits and challenges". Am. J. Obstet. Gynecol. 180 (3 Pt 2): S308–11. PMID 10076169.
- Kotz K, Alexander JL, Dennerstein L (2006). "Estrogen and androgen hormone therapy and well-being in surgically postmenopausal women". J Womens Health (Larchmt). 15 (8): 898–908. doi:10.1089/jwh.2006.15.898. PMID 17087613.
- Garefalakis M, Hickey M (2008). "Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence". Clin Interv Aging. 3 (1): 1–8. PMC 2544356. PMID 18488873.
- Somboonporn W (2006). "Androgen and menopause". Curr. Opin. Obstet. Gynecol. 18 (4): 427–32. doi:10.1097/01.gco.0000233938.36554.37. PMID 16794424.
- Davis S (2001). "Testosterone deficiency in women". J Reprod Med. 46 (3 Suppl): 291–6. PMID 11304877.
- Nieschlag E (2010). "Clinical trials in male hormonal contraception". Contraception. 82 (5): 457–70. doi:10.1016/j.contraception.2010.03.020. PMID 20933120.
- "Most steroid users are not athletes: study". Reuters. 2007-11-21. Retrieved 2014-01-03.
- Sjöqvist F, Garle M, Rane A (May 2008). "Use of doping agents, in particular anabolic steroids, in sports and society". Lancet. 371 (9627): 1872–82. doi:10.1016/S0140-6736(08)60801-6. PMID 18514731.
- Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS (1993). "Anabolic-androgenic steroid use in the United States". JAMA. 270 (10): 1217–21. doi:10.1001/jama.270.10.1217. PMID 8355384.
- McCabe SE, Brower KJ, West BT, Nelson TF, Wechsler H (2007). "Trends in non-medical use of anabolic steroids by U.S. college students: Results from four national surveys". Drug and Alcohol Dependence. 90 (2–3): 243–51. doi:10.1016/j.drugalcdep.2007.04.004. PMC 2383927. PMID 17512138.
- Parkinson AB, Evans NA (April 2006). "Anabolic androgenic steroids: a survey of 500 users". Med Sci Sports Exerc. 38 (4): 644–51. doi:10.1249/01.mss.0000210194.56834.5d. PMID 16679978.
- Cohen J, Collins R, Darkes J, Gwartney D (2007). "A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States". J Int Soc Sports Nutr. 4: 12. doi:10.1186/1550-2783-4-12. PMC 2131752. PMID 17931410.
- Copeland J, Peters R, Dillon P (March 1998). "A study of 100 anabolic-androgenic steroid users". Med. J. Aust. 168 (6): 311–2. PMID 9549549.
- Eastley, Tony (January 18, 2006). "Steroid study debunks user stereotypes". ABC. Retrieved 2014-01-03.
- Pope HG, Kanayama G, Ionescu-Pioggia M, Hudson JI (September 2004). "Anabolic steroid users' attitudes towards physicians". Addiction. 99 (9): 1189–94. doi:10.1111/j.1360-0443.2004.00781.x. PMID 15317640.
- Kanayama G, Barry S, Hudson JI, Pope HG (April 2006). "Body image and attitudes toward male roles in anabolic-androgenic steroid users". Am J Psychiatry. 163 (4): 697–703. doi:10.1176/appi.ajp.163.4.697. PMID 16585446.
- Grogan S, Shepherd S, Evans R, Wright S, Hunter G (Nov 2006). "Experiences of Anabolic Steroid Use". Journal of Health Psychology. 11 (6): 845–856. doi:10.1177/1359105306069080. PMID 17035257.
- Hickson RC, Czerwinski SM, Falduto MT, Young AP (1990). "Glucocorticoid antagonism by exercise and androgenic-anabolic steroids". Medicine & Science in Sports & Exercise. 22 (3): 331–40. doi:10.1249/00005768-199006000-00010. PMID 2199753.
- Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 1185–1186. ISBN 978-0-7817-1750-2.
- Llewellyn, William (2011). Anabolics. Molecular Nutrition Llc. pp. 533–, 402–412, 460–467. ISBN 978-0-9828280-1-4.
- Rahnema CD, Crosnoe LE, Kim ED (March 2015). "Designer steroids - over-the-counter supplements and their androgenic component: review of an increasing problem". Andrology. 3 (2): 150–5. doi:10.1111/andr.307. PMID 25684733.
- Chrousos, George P. (2012). "The Gonadal Hormones & Inhibitors". In Katzung, Bertram G. Basic & Clinical Pharmacology. New York London: McGraw-Hill Medical McGraw-Hill distributor. ISBN 0071764011.
- Mutzebaugh C (1998). "Does the choice of alpha-AAS really make a difference?". HIV Hotline. 8 (5–6): 10–1. PMID 11366379.
- Casavant MJ, Blake K, Griffith J, Yates A, Copley LM (2007). "Consequences of use of anabolic androgenic steroids". Pediatr. Clin. North Am. 54 (4): 677–90, x. doi:10.1016/j.pcl.2007.04.001. PMID 17723870.
- Pope HG, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S (2014). "Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement". Endocr. Rev. 35 (3): 341–75. doi:10.1210/er.2013-1058. PMC 4026349. PMID 24423981.
- Fragkaki AG, Angelis YS, Koupparis M, Tsantili-Kakoulidou A, Kokotos G, Georgakopoulos C (2009). "Structural characteristics of anabolic androgenic steroids contributing to binding to the androgen receptor and to their anabolic and androgenic activities. Applied modifications in the steroidal structure". Steroids. 74 (2): 172–97. doi:10.1016/j.steroids.2008.10.016. PMID 19028512.
- Nieschlag E, Vorona E (2015). "MECHANISMS IN ENDOCRINOLOGY: Medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions". Eur. J. Endocrinol. 173 (2): R47–58. doi:10.1530/EJE-15-0080. PMID 25805894.
- Hall RC, Hall RC, Chapman MJ (2005). "Psychiatric complications of anabolic steroid abuse". Psychosomatics. 46 (4): 285–90. doi:10.1176/appi.psy.46.4.285. PMID 16000671.
- Trenton AJ, Currier GW (2005). "Behavioural manifestations of anabolic steroid use". CNS Drugs. 19 (7): 571–95. doi:10.2165/00023210-200519070-00002. PMID 15984895.
- Vanberg P, Atar D (2010). "Androgenic anabolic steroid abuse and the cardiovascular system". Handb Exp Pharmacol (195): 411–57. doi:10.1007/978-3-540-79088-4_18. PMID 20020375.
- Achar S, Rostamian A, Narayan SM (2010). "Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm". Am. J. Cardiol. 106 (6): 893–901. doi:10.1016/j.amjcard.2010.05.013. PMC 4111565. PMID 20816133.
- Solimini R, Rotolo MC, Mastrobattista L, Mortali C, Minutillo A, Pichini S, Pacifici R, Palmi I (2017). "Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping". Eur Rev Med Pharmacol Sci. 21 (1 Suppl): 7–16. PMID 28379599.
- Brenu EW, McNaughton L, Marshall-Gradisnik SM (2011). "Is there a potential immune dysfunction with anabolic androgenic steroid use?: A review". Mini Rev Med Chem. 11 (5): 438–45. doi:10.2174/138955711795445907. PMID 21443507.
- Grace F, Sculthorpe N, Baker J, Davies B (2003). "Blood pressure and rate pressure product response in males using high-dose anabolic-androgenic steroids (AAS)". J Sci Med Sport. 6 (3): 307–12. doi:10.1016/S1440-2440(03)80024-5. PMID 14609147.
- "DailyMed: About DailyMed". Dailymed.nlm.nih.gov. Retrieved 2008-11-03.
- Bagatell CJ, Knopp RH, Vale WW, Rivier JE, Bremner WJ (1992). "Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels". Annals of Internal Medicine. 116 (12 Pt 1): 967–73. doi:10.7326/0003-4819-116-12-967. PMID 1586105.
- Mewis C, Spyridopoulos I, Kühlkamp V, Seipel L (1996). "Manifestation of severe coronary heart disease after anabolic drug abuse". Clinical Cardiology. 19 (2): 153–5. doi:10.1002/clc.4960190216. PMID 8821428.
- Melnik B, Jansen T, Grabbe S (2007). "Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem". Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 5 (2): 110–7. doi:10.1111/j.1610-0387.2007.06176.x. PMID 17274777.
- Vierhapper H, Maier H, Nowotny P, Waldhäusl W (July 2003). "Production rates of testosterone and of dihydrotestosterone in female pattern hair loss". Metab. Clin. Exp. 52 (7): 927–9. doi:10.1016/S0026-0495(03)00060-X. PMID 12870172.
- Irving LM, Wall M, Neumark-Sztainer D, Story M (2002). "Steroid use among adolescents: findings from Project EAT". The Journal of Adolescent Health. 30 (4): 243–52. doi:10.1016/S1054-139X(01)00414-1. PMID 11927236.
- "Known and Probable Human Carcinogens". American Cancer Society. 2011-06-29.
- Sullivan ML, Martinez CM, Gallagher EJ (1999). "Atrial fibrillation and anabolic steroids". The Journal of Emergency Medicine. 17 (5): 851–7. doi:10.1016/S0736-4679(99)00095-5. PMID 10499702.
- Dickerman RD, Schaller F, McConathy WJ (1998). "Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid Use". Cardiology. 90 (2): 145–8. doi:10.1159/000006834. PMID 9778553.
- George KP, Wolfe LA, Burggraf GW (1991). "The 'athletic heart syndrome'. A critical review". Sports Medicine. 11 (5): 300–30. doi:10.2165/00007256-199111050-00003. PMID 1829849.
- Dickerman RD, Schaller F, Zachariah NY, McConathy WJ (1997). "Left ventricular size and function in elite bodybuilders using anabolic steroids". Clin J Sport Med. 7 (2): 90–3. doi:10.1097/00042752-199704000-00003. PMID 9113423.
- Salke RC, Rowland TW, Burke EJ (1985). "Left ventricular size and function in body builders using anabolic steroids". Medicine & Science in Sports & Exercise. 17 (6): 701–4. doi:10.1249/00005768-198512000-00014. PMID 4079743.
- Tokar, Steve (February 2006). "Liver Damage And Increased Heart Attack Risk Caused By Anabolic Steroid Use". University of California – San Francisco. Retrieved 2007-04-24.
- Wit JM, Oostdijk W (2015). "Novel approaches to short stature therapy". Best Practice & Research. Clinical Endocrinology & Metabolism. 29 (3): 353–66. doi:10.1016/j.beem.2015.01.003. PMID 26051296.
- Marcus R, Korenman SG (1976). "Estrogens and the human male". Annu Rev Med. 27: 357–70. doi:10.1146/annurev.me.27.020176.002041. PMID 779604.
- Matsumoto AM (1990). "Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production". J. Clin. Endocrinol. Metab. 70 (1): 282–7. doi:10.1210/jcem-70-1-282. PMID 2104626.
- Hoffman JR, Ratamess NA (June 1, 2006). "Medical Issues Associated with Anabolic Steroid Use: Are they Exaggerated?" (PDF). Journal of Sports Science and Medicine. Archived (PDF) from the original on 20 June 2007. Retrieved 2007-05-08.
- Meriggiola MC, Costantino A, Bremner WJ, Morselli-Labate AM (2002). "Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen". J. Androl. 23 (5): 684–90. PMID 12185103.
- Alén M, Reinilä M, Vihko R (1985). "Response of serum hormones to androgen administration in power athletes". Medicine & Science in Sports & Exercise. 17 (3): 354–9. doi:10.1249/00005768-198506000-00009. PMID 2991700.
- Franke WW, Berendonk B (July 1997). "Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government". Clinical Chemistry. 43 (7): 1262–79. PMID 9216474.
- Manikkam M, Crespi EJ, Doop DD, Herkimer C, Lee JS, Yu S, Brown MB, Foster DL, Padmanabhan V (February 2004). "Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep". Endocrinology. 145 (2): 790–8. doi:10.1210/en.2003-0478. PMID 14576190.
- Herlitz LC, Markowitz GS, Farris AB, Schwimmer JA, Stokes MB, Kunis C, Colvin RB, D'Agati VD (October 29, 2009). Development of FSGS Following Anabolic Steroid Use in Bodybuilders (PDF). 42nd Annual Meeting and Scientific Exposition of the American Society of Nephrology. "Bodybuilding With Steroids Damages Kidneys". Lay summary – ScienceDaily (October 30, 2009).
- Nutt D, King LA, Saulsbury W, Blakemore C (March 2007). "Development of a rational scale to assess the harm of drugs of potential misuse". Lancet. 369 (9566): 1047–53. doi:10.1016/S0140-6736(07)60464-4. PMID 17382831.
- Kanayama G, Hudson JI, Pope HG (November 2008). "Long-Term Psychiatric and Medical Consequences of Anabolic-Androgenic Steroid Abuse: A Looming Public Health Concern?". Drug Alcohol Depend. 98 (1–2): 1–12. doi:10.1016/j.drugalcdep.2008.05.004. PMC 2646607. PMID 18599224.
- Brower KJ (October 2002). "Anabolic steroid abuse and dependence". Curr Psychiatry Rep. 4 (5): 377–87. doi:10.1007/s11920-002-0086-6. PMID 12230967.
- Fudala PJ, Weinrieb RM, Calarco JS, Kampman KM, Boardman C (2003). "An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: seven case studies". Annals of Clinical Psychiatry. 15 (2): 121–30. doi:10.3109/10401230309085677. PMID 12938869.
- Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS (2006). "Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse". Eur. Psychiatry. 21 (8): 551–62. doi:10.1016/j.eurpsy.2005.09.001. PMID 16356691.
- Rashid H, Ormerod S, Day E (2007). "Anabolic androgenic steroids: What the psychiatrist needs to know". Advances in Psychiatric Treatment. 13 (3): 203–211. doi:10.1192/apt.bp.105.000935.
- Cooper CJ, Noakes TD, Dunne T, Lambert MI, Rochford K (September 1996). "A high prevalence of abnormal personality traits in chronic users of anabolic-androgenic steroids". Br J Sports Med. 30 (3): 246–50. doi:10.1136/bjsm.30.3.246. PMC 1332342. PMID 8889121.
- "Dr. Ritchi Morris". Vitalquests.org. Archived from the original on 2013-12-03. Retrieved 2013-12-01.
- Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG (December 2009). "Anabolic-androgenic steroid dependence: an emerging disorder". Addiction. 104 (12): 1966–78. doi:10.1111/j.1360-0443.2009.02734.x. PMC 2780436. PMID 19922565.
- Eisenberg ER, Galloway GP. "Anabolic androgenic steroids". In Lowinson JH, Ruiz P, Millman RB. Substance Abuse: A Comprehensive Textbook. Lippincott Williams & Wilkins. ASIN B0049VACMW.
- Lindström M, Nilsson AL, Katzman PL, Janzon L, Dymling JF (1990). "Use of anabolic-androgenic steroids among body builders—frequency and attitudes". J. Intern. Med. 227 (6): 407–11. doi:10.1111/j.1365-2796.1990.tb00179.x. PMID 2351927.
- Lenahan P (2003). Anabolic Steroids: And Other Performance-enhancing Drugs. London: Taylor & Francis. ISBN 0-415-28030-3.
- Thiblin I, Petersson A (February 2005). "Pharmacoepidemiology of anabolic androgenic steroids: a review". Fundam Clin Pharmacol. 19 (1): 27–44. doi:10.1111/j.1472-8206.2004.00298.x. PMID 15660958.
- Beaver KM, Vaughn MG, Delisi M, Wright JP (December 2008). "Anabolic-Androgenic Steroid Use and Involvement in Violent Behavior in a Nationally Representative Sample of Young Adult Males in the United States". Am J Public Health. 98 (12): 2185–7. doi:10.2105/AJPH.2008.137018. PMC 2636528. PMID 18923108.
- Bahrke MS, Yesalis CE, Wright JE (1996). "Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update". Sports Medicine. 22 (6): 367–90. doi:10.2165/00007256-199622060-00005. PMID 8969015.
- Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R (July 1996). "The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men". N. Engl. J. Med. 335 (1): 1–7. doi:10.1056/NEJM199607043350101. PMID 8637535.
- Tricker R, Casaburi R, Storer TW, Clevenger B, Berman N, Shirazi A, Bhasin S (October 1996). "The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men—a clinical research center study". J. Clin. Endocrinol. Metab. 81 (10): 3754–8. doi:10.1210/jcem.81.10.8855834. PMID 8855834.
- Pope HG, Kouri EM, Hudson JI (February 2000). "Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial". Arch. Gen. Psychiatry. 57 (2): 133–40, discussion 155–6. doi:10.1001/archpsyc.57.2.133. PMID 10665615.
- Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS, Toli PN (2006). "Psychiatric and hostility factors related to use of anabolic steroids in monozygotic twins". Eur. Psychiatry. 21 (8): 563–9. doi:10.1016/j.eurpsy.2005.11.002. PMID 16529916.
- Perry PJ, Kutscher EC, Lund BC, Yates WR, Holman TL, Demers L (May 2003). "Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use". J. Forensic Sci. 48 (3): 646–51. PMID 12762541.
- "Teens & Steroids: A Dangerous Mix". CBS Broadcasting Inc. 2004-06-03. Archived from the original on 10 July 2007. Retrieved 2007-06-27.
- Uzych L (February 1992). "Anabolic-androgenic steroids and psychiatric-related effects: a review". Can J Psychiatry. 37 (1): 23–8. PMID 1551042.
- "Anabolic Steroids and Suicide – A Brief Review of the Evidence". Thinksteroids.com. 2005-07-12. Retrieved 2013-12-01.
- El Osta R, Almont T, Diligent C, Hubert N, Eschwège P, Hubert J (2016). "Anabolic steroids abuse and male infertility". Basic Clin Androl. 26 (2). doi:10.1186/s12610-016-0029-4. PMID 26855782.
- Kickman AT (2008). "Pharmacology of anabolic steroids". Br J Pharmacol. 154 (3): 502–521. doi:10.1038/bjp.2008.165. PMC 2439524. PMID 18500378.
- Stromme SB, Meen HD, Aakvaag A (1974). "Effects of an androgenic-anabolic steroid on strength development and plasma testosterone levels in normal males". Med Sci Sports. 6 (3): 203–208. PMID 4437350.
- Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S (2014). "The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis". Ann Epidemiol. 24 (5): 383–398. doi:10.1007/s40279-017-0709-z. PMID 24582699.
- Christou MA, Christou PA, Markozannes G, Tsatsoulis A, Mastorakos G, Tigas S (2017). "Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis". Sports Med. 47 (9): 1869–1883. doi:10.1007/s40279-017-0709-z. PMID 28258581.
- Pereira de Jésus-Tran K, Côté PL, Cantin L, Blanchet J, Labrie F, Breton R (2006). "Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity". Protein Sci. 15 (5): 987–99. doi:10.1110/ps.051905906. PMC 2242507. PMID 16641486.
- Lavery DN, McEwan IJ (2005). "Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations". Biochem. J. 391 (Pt 3): 449–64. doi:10.1042/BJ20050872. PMC 1276946. PMID 16238547.
- Cheskis BJ (2004). "Regulation of cell signalling cascades by steroid hormones". J. Cell. Biochem. 93 (1): 20–7. doi:10.1002/jcb.20180. PMID 15352158.
- Roselli CE (1998). "The effect of anabolic-androgenic steroids on aromatase activity and androgen receptor binding in the rat preoptic area". Brain Res. 792 (2): 271–6. doi:10.1016/S0006-8993(98)00148-6. PMID 9593936.
- Brodsky IG, Balagopal P, Nair KS (1996). "Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study". J. Clin. Endocrinol. Metab. 81 (10): 3469–75. doi:10.1210/jc.81.10.3469. PMID 8855787.
- Hickson RC, Czerwinski SM, Falduto MT, Young AP (1990). "Glucocorticoid antagonism by exercise and androgenic-anabolic steroids". Med Sci Sports Exerc. 22 (3): 331–40. doi:10.1249/00005768-199006000-00010. PMID 2199753.
- Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S (2003). "Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway". Endocrinology. 144 (11): 5081–8. doi:10.1210/en.2003-0741. PMID 12960001.
- Schroeder ET, Vallejo AF, Zheng L, Stewart Y, Flores C, Nakao S, Martinez C, Sattler FR (2005). "Six-week improvements in muscle mass and strength during androgen therapy in older men". J Gerontol A Biol Sci Med Sci. 60 (12): 1586–92. doi:10.1093/gerona/60.12.1586. PMID 16424293.
- Grunfeld C, Kotler DP, Dobs A, Glesby M, Bhasin S (2006). "Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study". J Acquir Immune Defic Syndr. 41 (3): 304–14. doi:10.1097/01.qai.0000197546.56131.40. PMID 16540931.
- Giorgi A, Weatherby RP, Murphy PW (1999). "Muscular strength, body composition and health responses to the use of testosterone enanthate: a double blind study". Journal of science and medicine in sport / Sports Medicine Australia. 2 (4): 341–55. doi:10.1016/S1440-2440(99)80007-3. PMID 10710012.
- Kuhn CM (2002). "Anabolic steroids". Recent Prog. Horm. Res. 57: 411–34. doi:10.1210/rp.57.1.411. PMID 12017555.
- "How Anabolic Steroids Alter Both Men And Women". casapalmera.com. Retrieved 2 January 2014.
- Hershberger LG, Shipley EG, Meyer RK (1953). "Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method". Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). 83 (1): 175–80. doi:10.3181/00379727-83-20301. PMID 13064212.
- Hervey GR, Hutchinson I, Knibbs AV, Burkinshaw L, Jones PR, Norgan NG, Levell MJ (October 1976). ""Anabolic" effects of methandienone in men undergoing athletic training". Lancet. 2 (7988): 699–702. doi:10.1016/S0140-6736(76)90001-5. PMID 61389.
- Hervey GR, Knibbs AV, Burkinshaw L, Morgan DB, Jones PR, Chettle DR, Vartsky D (April 1981). "Effects of methandienone on the performance and body composition of men undergoing athletic training". Clin. Sci. 60 (4): 457–61. PMID 7018798.
- Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW (December 2001). "Testosterone dose-response relationships in healthy young men". Am. J. Physiol. Endocrinol. Metab. 281 (6): E1172–81. PMID 11701431.
- Imperato-McGinley J, Peterson RE, Gautier T, Sturla E (May 1979). "Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5alpha-reductase deficiency". The New England Journal of Medicine. 300 (22): 1233–7. doi:10.1056/NEJM197905313002201. PMID 431680.
- Marks LS (2004). "5α-reductase: history and clinical importance". Rev Urol. 6 Suppl 9: S11–21. PMC 1472916. PMID 16985920.
- Sloane E (2002). Biology of Women. Cengage Learning. pp. 160–. ISBN 0-7668-1142-5.
- Hanno PM, Guzzi TJ, Malkowicz SB, J Wein A (26 January 2014). Penn Clinical Manual of Urology. Elsevier Health Sciences. pp. 782–. ISBN 978-0-323-24466-4.
- Jain NK, Siddiqi M, Weisburger JH (2006). Protective Effects of Tea on Human Health. CABI. pp. 95–. ISBN 978-1-84593-113-1.
- Harper C (1 August 2007). Intersex. Berg. pp. 123–. ISBN 978-1-84788-339-1.
- Bergink EW, Janssen PS, Turpijn EW, van der Vies J (June 1985). "Comparison of the receptor binding properties of nandrolone and testosterone under in vitro and in vivo conditions". J. Steroid Biochem. 22 (6): 831–6. doi:10.1016/0022-4731(85)90293-6. PMID 4021486.
- Bergink EW, Geelen JA, Turpijn EW (1985). "Metabolism and receptor binding of nandrolone and testosterone under in vitro and in vivo conditions". Acta Endocrinol Suppl (Copenh). 271: 31–7. doi:10.1530/acta.0.109S0031. PMID 3865479.
- Basaria S, Wahlstrom JT, Dobs AS (2001). "Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases". J. Clin. Endocrinol. Metab. 86 (11): 5108–17. doi:10.1210/jcem.86.11.7983. PMID 11701661.
[...] in a recent animal study, Hsiao et al. (10) found two different kinds of androgen response elements that could respond differentially to T and DHT. Therefore, it is possible that a selective androgen response element sequence may play a role in differential T vs. DHT AR trans-activation.
- Basaria S, Dobs AS (2001). "Hypogonadism and androgen replacement therapy in elderly men". Am. J. Med. 110 (7): 563–72. doi:10.1016/s0002-9343(01)00663-5. PMID 11343670.
Although both testosterone and dihydrotestosterone activate the same androgen receptor, differences in the sequence of androgen response elements are responsible for differential regulation of these hormones (21).
- Wang C, Liu Y, Cao JM (2014). "G protein-coupled receptors: extranuclear mediators for the non-genomic actions of steroids". Int J Mol Sci. 15 (9): 15412–25. doi:10.3390/ijms150915412. PMC 4200746. PMID 25257522.
- Thomas P, Converse A, Berg HA (2017). "ZIP9, a novel membrane androgen receptor and zinc transporter protein". Gen. Comp. Endocrinol. doi:10.1016/j.ygcen.2017.04.016. PMID 28479083.
- Mongan NP, Tadokoro-Cuccaro R, Bunch T, Hughes IA (2015). "Androgen insensitivity syndrome". Best Pract. Res. Clin. Endocrinol. Metab. 29 (4): 569–80. doi:10.1016/j.beem.2015.04.005. PMID 26303084.
- Eric S. Orwoll; John P. Bilezikian; Dirk Vanderschueren (30 November 2009). Osteoporosis in Men: The Effects of Gender on Skeletal Health. Academic Press. pp. 114–. ISBN 978-0-08-092346-8.
- Pi M, Quarles LD (2012). "GPRC6A regulates prostate cancer progression". Prostate. 72 (4): 399–409. doi:10.1002/pros.21442. PMC 3183291. PMID 21681779.
- Wu FC, Balasubramanian R, Mulders TM, Coelingh-Bennink HJ (January 1999). "Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism". J. Clin. Endocrinol. Metab. 84 (1): 112–22. doi:10.1210/jcem.84.1.5412. PMID 9920070.
- Bitran D, Kellogg CK, Hilvers RJ (1993). "Treatment with an anabolic-androgenic steroid affects anxiety-related behavior and alters the sensitivity of cortical GABAA receptors in the rat". Horm Behav. 27 (4): 568–83. doi:10.1006/hbeh.1993.1041. PMID 8294123.
- Masonis AE, McCarthy MP (1995). "Direct effects of the anabolic/androgenic steroids, stanozolol and 17α-methyltestosterone, on benzodiazepine binding to the γ-aminobutyric acidA receptor". Neurosci. Lett. 189 (1): 35–8. doi:10.1016/0304-3940(95)11445-3. PMID 7603620.
- Masonis AE, McCarthy MP (1996). "Effects of the androgenic/anabolic steroid stanozolol on GABAA receptor function: GABA-stimulated 36Cl− influx and [35S] TBPS binding". J. Pharmacol. Exp. Ther. 279 (1): 186–93. PMID 8858992.
- Rivera-Arce JC, Morales-Crespo L, Vargas-Pinto N, Velázquez KT, Jorge JC (2006). "Central effects of the anabolic steroid 17alpha methyltestosterone in female anxiety". Pharmacol. Biochem. Behav. 84 (2): 275–81. doi:10.1016/j.pbb.2006.05.009. PMID 16814373.
- Henderson LP (2007). "Steroid modulation of GABAA receptor-mediated transmission in the hypothalamus: effects on reproductive function". Neuropharmacology. 52 (7): 1439–53. doi:10.1016/j.neuropharm.2007.01.022. PMC 1985867. PMID 17433821.
- Schwartzer JJ, Ricci LA, Melloni RH (2009). "Interactions between the dopaminergic and GABAergic neural systems in the lateral anterior hypothalamus of aggressive AAS-treated hamsters". Behav. Brain Res. 203 (1): 15–22. doi:10.1016/j.bbr.2009.04.007. PMID 19376158.
- Schänzer W (1996). "Metabolism of anabolic androgenic steroids" (PDF). Clin. Chem. 42 (7): 1001–20. PMID 8674183.
- Delettré J, Mornon JP, Lepicard G, Ojasoo T, Raynaud JP (January 1980). "Steroid flexibility and receptor specificity". J. Steroid Biochem. 13 (1): 45–59. doi:10.1016/0022-4731(80)90112-0. PMID 7382482.
- Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP (1987). "Towards the mapping of the progesterone and androgen receptors". J. Steroid Biochem. 27 (1–3): 255–69. doi:10.1016/0022-4731(87)90317-7. PMID 3695484.
- Raynaud JP, Bouton MM, Moguilewsky M, Ojasoo T, Philibert D, Beck G, Labrie F, Mornon JP (January 1980). "Steroid hormone receptors and pharmacology". J. Steroid Biochem. 12: 143–57. doi:10.1016/0022-4731(80)90264-2. PMID 7421203.
- Ojasoo T, Raynaud JP (November 1978). "Unique steroid congeners for receptor studies". Cancer Res. 38 (11 Pt 2): 4186–98. PMID 359134.
- Ojasoo T, Raynaud JP, Doé JC (January 1994). "Affiliations among steroid receptors as revealed by multivariate analysis of steroid binding data". J. Steroid Biochem. Mol. Biol. 48 (1): 31–46. doi:10.1016/0960-0760(94)90248-8. PMID 8136304.
- Saartok T, Dahlberg E, Gustafsson JA (June 1984). "Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin". Endocrinology. 114 (6): 2100–6. doi:10.1210/endo-114-6-2100. PMID 6539197.
- Cunningham GR, Tindall DJ, Lobl TJ, Campbell JA, Means AR (September 1981). "Steroid structural requirements for high affinity binding to human sex steroid binding protein (SBP)". Steroids. 38 (3): 243–62. doi:10.1016/0039-128X(81)90061-1. PMID 7197818.
- Pugeat MM, Dunn JF, Nisula BC (July 1981). "Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma". J. Clin. Endocrinol. Metab. 53 (1): 69–75. doi:10.1210/jcem-53-1-69. PMID 7195405.
- Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
- Potts GO, Arnold A, Beyler AL (1976). "Dissociation of the Androgenic and Other Hormonal Activities from the Protein Anabolic Effects of Steroids": 361–406. doi:10.1007/978-3-642-66353-6_11.
- Charles D. Kochakian (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 370–373, 380. ISBN 978-3-642-66353-6.
- Attardi BJ, Hild SA, Koduri S, Pham T, Pessaint L, Engbring J, Till B, Gropp D, Semon A, Reel JR (October 2010). "The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects". The Journal of Steroid Biochemistry and Molecular Biology. 122 (4): 212–8. doi:10.1016/j.jsbmb.2010.06.009. PMC 2949447. PMID 20599615.
- Orwoll, Eric S.; Bilezikian, John P.; Vanderschueren, Dirk (30 November 2009). Osteoporosis in Men: The Effects of Gender on Skeletal Health. Academic Press. pp. 296–. ISBN 978-0-08-092346-8.
- Fillit, Howard M.; Rockwood, Kenneth; Woodhouse, Kenneth (10 May 2010). Brocklehurst's Textbook of Geriatric Medicine and Gerontology. Elsevier Health Sciences. pp. 166–167. ISBN 1-4377-2075-7.
- Thieme, Detlef; Hemmersbach, Peter (18 December 2009). Doping in Sports. Springer Science & Business Media. pp. 470–. ISBN 978-3-540-79088-4.
- Attardi BJ, Pham TC, Radler LC, Burgenson J, Hild SA, Reel JR (June 2008). "Dimethandrolone (7,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase". The Journal of Steroid Biochemistry and Molecular Biology. 110 (3–5): 214–22. doi:10.1016/j.jsbmb.2007.11.009. PMC 2575079. PMID 18555683.
- Tan RS, Scally MC (2009). "Anabolic steroid-induced hypogonadism—towards a unified hypothesis of anabolic steroid action". Med. Hypotheses. 72 (6): 723–8. doi:10.1016/j.mehy.2008.12.042. PMID 19231088.
Regulation of the secretion of GnRH, FSH, and LH occurs partially by the negative feedback of testosterone and estradiol at the level of the hypothalamo-pituitary. Estradiol has a much larger, inhibitory effect than testosterone, being 200-fold more effective in suppressing LH secretion [57–61].
- Suvisaari, Janne (2000). 7α-Methyl-19-nortestosterone (MENT) Pharmacokinetics and Antigonadotropic Effects in Men (PDF). Helsinki: University of Helsinki. p. 14. ISBN 952-91-2950-5.
Androgens, estrogens and progestins exert a negative feedback effect on the secretion of GnRH and LH by their actions on the pituitary and the hypothalamus. Most of the negative feedback effect of androgens is caused by their estrogenic metabolites produced by aromatization. 5α-Reduction does not seem to be necessary for the negative feedback effect of testosterone. (Rittmaster et al, 1992; Kumar et al, 1995a; Hayes et al, 2000).
- Attardi BJ, Hild SA, Reel JR (June 2006). "Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity". Endocrinology. 147 (6): 3016–26. doi:10.1210/en.2005-1524. PMID 16497801.
- Warren, Michelle P.; Constantini, Naama W. (1 May 2000). Sports Endocrinology. Springer Science & Business Media. pp. 458–. ISBN 978-1-59259-016-2.
- Haff, G. Gregory; Triplett, N. Travis (23 September 2015). Essentials of Strength Training and Conditioning 4th Edition. Human Kinetics. pp. 233–. ISBN 978-1-4925-0162-6.
- Lemke, Thomas L.; Williams, David A. (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1360–. ISBN 978-1-60913-345-0.
- Karch, Steven B.; Drummer, Olaf (26 December 2001). Karch's Pathology of Drug Abuse, Third Edition. CRC Press. pp. 489–. ISBN 978-1-4200-4211-5.
- van Amsterdam J, Opperhuizen A, Hartgens F (2010). "Adverse health effects of anabolic-androgenic steroids". Regul. Toxicol. Pharmacol. 57 (1): 117–23. doi:10.1016/j.yrtph.2010.02.001. PMID 20153798.
- Wilson JD (1988). "Androgen abuse by athletes". Endocr. Rev. 9 (2): 181–99. doi:10.1210/edrv-9-2-181. PMID 3042375.
- Jameson, J. Larry; De Groot, Leslie J. (25 February 2015). Endocrinology: Adult and Pediatric. Elsevier Health Sciences. pp. 2391–. ISBN 978-0-323-32195-2.
- Nieschlag, Eberhard; Behre, Hermann M.; Nieschlag, Susan (26 July 2012). Testosterone: Action, Deficiency, Substitution. Cambridge University Press. pp. 374–. ISBN 978-1-107-01290-5.
- Cameron, Ross; Feuer, George; de la Iglesia, Felix (6 December 2012). Drug-Induced Hepatotoxicity. Springer Science & Business Media. pp. 166–. ISBN 978-3-642-61013-4.
- Shahidi NT (2001). "A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids". Clin Ther. 23 (9): 1355–90. doi:10.1016/s0149-2918(01)80114-4. PMID 11589254.
- Büttner A, Thieme D (2009). "Side effects of anabolic androgenic steroids: pathological findings and structure-activity relationships". Handbook of Experimental Pharmacology. 195 (195): 459–84. doi:10.1007/978-3-540-79088-4_19. PMID 20020376.
- Mareck U, Geyer H, Opfermann G, Thevis M, Schänzer W (July 2008). "Factors influencing the steroid profile in doping control analysis". J Mass Spectrom. 43 (7): 877–91. doi:10.1002/jms.1457. PMID 18570179.
- Fragkaki AG, Angelis YS, Tsantili-Kakoulidou A, Koupparis M, Georgakopoulos C (May 2009). "Schemes of metabolic patterns of anabolic androgenic steroids for the estimation of metabolites of designer steroids in human urine". J. Steroid Biochem. Mol. Biol. 115 (1–2): 44–61. doi:10.1016/j.jsbmb.2009.02.016. PMID 19429460.
- Blackledge RD (August 2009). "Bad science: the instrumental data in the Floyd Landis case". Clin. Chim. Acta. 406 (1–2): 8–13. doi:10.1016/j.cca.2009.05.016. PMID 19465014.
- Baselt, Randall Clint (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 95, 393, 403, 649, 695, 952, 962, 1078, 1156, 1170, 1442, 1501, 1581. ISBN 978-0-9626523-7-0.
- Hoberman JM, Yesalis CE (1995). "The history of synthetic testosterone". Scientific American. 272 (2): 76–81. doi:10.1038/scientificamerican0295-76. PMID 7817189.
- Freeman ER, Bloom DA, McGuire EJ (2001). "A brief history of testosterone". Journal of Urology. 165 (2): 371–373. doi:10.1097/00005392-200102000-00004. PMID 11176375.
- David K, Dingemanse E, Freud J, Laqueur L (1935). "Uber krystallinisches mannliches Hormon aus Hoden (Testosteron) wirksamer als aus harn oder aus Cholesterin bereitetes Androsteron". Hoppe-Seyler's Z Physiol Chem. 233 (5–6): 281–283. doi:10.1515/bchm2.1935.233.5-6.281.
- Butenandt A, Hanisch G (1935). "Über die Umwandlung des Dehydro-androsterons in Δ4-Androsten-ol-(17)-0n-(3) (Testosteron); ein Weg zur Darstellung des Testosterons aus Cholesterin (Vorläuf. Mitteil.)" [On the conversion of dehydro-Δ4-androstene androsterons in-ol (17) 0n (3) (testosterone), a way to represent the testosterone from cholesterol (Vorläuf. msgs.)]. Berichte der deutschen chemischen Gesellschaft (A and B Series) (in German). 68 (9): 1859–62. doi:10.1002/cber.19350680937.
- Ruzicka L, Wettstein A (1935). "Sexualhormone VII. Uber die kunstliche Herstellung des Testikelhormons. Testosteron (Androsten-3-one-17-ol.)" [Sex hormones VII About the artificial production of testosterone Testikelhormons (androstene-3-one-17-ol)]. Helvetica Chimica Acta (in German). 18: 1264–75. doi:10.1002/hlca.193501801176.
- Taylor WN (January 1, 2009). Anabolic Steroids and the Athlete. McFarland & Company. p. 181. ISBN 0-7864-1128-7.
- Suarez R, Senior Correspondent, Kelman J, physician (2002-11-18). "President Kennedy's Health Secrets". PBS NewsHour. Public Broadcasting System.
- Calfee R, Fadale P (2006). "Popular ergogenic drugs and supplements in young athletes". Pediatrics. 117 (3): e577–89. doi:10.1542/peds.2005-1429. PMID 16510635.
- Justin Peters The Man Behind the Juice, Slate Friday, Feb. 18, 2005. Retrieved 29 April 2008
- Kochakian, Charles D. (1946). "The Protein Anabolic Effects of Steroid Hormones". 4: 255–310. doi:10.1016/S0083-6729(08)61085-7. ISSN 0083-6729.
In recent years several laboratories (Kochakian, Albright, Wilkins) have entertained the hope of finding a protein anabolic steroid without any, or with only minor, sexual effects. These studies have received special impetus and encouragement from the observation of Kochakian that certain steroids have greater renotrophic (anabolic?) than androgenic effects.
- Walter Sneader (23 June 2005). Drug Discovery: A History. John Wiley & Sons. pp. 206–. ISBN 978-0-471-89979-2.
- Camille Georges Wermuth (2 May 2011). The Practice of Medicinal Chemistry. Academic Press. pp. 34–. ISBN 978-0-08-056877-5.
- James Edward Wright (1994). Altered States: The Use and Abuse of Anabolic Steroids. Masters Press. p. 33. ISBN 978-1-57028-013-9.
- United States. Patent Office (1957). Official Gazette of the United States Patent Office. U.S. Patent Office.
- Ashraf Mozayani; Lionel Raymon (18 September 2011). Handbook of Drug Interactions: A Clinical and Forensic Guide. Springer Science & Business Media. pp. 651–. ISBN 978-1-61779-222-9.
- "Title 21 United States Code (USC) Controlled Substances Act". US Department of Justice. Archived from the original on 24 July 2009. Retrieved 2009-09-07.
- Controlled Drugs and Substances Act, S.C. 1996, c. 19, s. 4(7) (Controlled Drugs and Substances Act at Department of Justice)
- Deacon, James (2 May 1994). "Biceps in a bottle". Maclean's: 52.
- "Steroids". Australian Institute of Criminology. 2006. Archived from the original on 2007-04-05. Retrieved 2007-05-06.
- H.R. 4658
- "News from DEA, Congressional Testimony, 03/16/04". Archived from the original on February 6, 2007. Retrieved 2007-04-24.
- "Patient.info Controlled Drugs". Egton Medical Information Systems Limited. Retrieved 8 August 2013.
- "FIFA Anit-Doping Regulations" (PDF). FIFA. Retrieved 2013-12-01.
- "Olympic movement anti-doping code" (PDF). International Olympic Committee. 1999. Retrieved 2007-05-06.
- "The nba and nbpa anti-drug program". NBA Policy. findlaw.com. 1999. Retrieved 2007-05-06.
- "NHL/NHLPA performance-enhancing substances program summary". nhlpa.com. Archived from the original on 2 June 2007. Retrieved 2007-05-06.
- "List of Prohibited Substances" (PDF). nflpa.com. 2006. Archived from the original (PDF) on 2007-06-20. Retrieved 2007-05-06.
- "World anti-doping code" (PDF). WADA. 2003. Archived from the original (PDF) on 7 August 2007. Retrieved 2007-07-10.
- "Prohibited list of 2005" (PDF). WADA. 2005. Archived from the original (PDF) on 2007-06-20. Retrieved 2007-05-06.
- "Spain's senate passes anti-doping law". Herald Tribune. Associated Press. October 5, 2006. Archived from the original on October 12, 2006. Retrieved 2007-05-06.
- Johnson, Kevin (2006-02-20). "Italian anti-doping laws could mean 3 years in jail". USA Today. Retrieved 2007-05-06.
- "Act on promotion of doping-free sport" (PDF). kum.dk. 2004. Retrieved 2016-09-04.
- "Protection of health of athletes and the fight against doping" (PDF). WADA. 2006. Archived from the original (PDF) on 2007-06-20. Retrieved 2007-05-06.
- "Anti-doping legislation in the netherlands" (PDF). WADA. 2006. Archived from the original (PDF) on 2007-06-20. Retrieved 2007-05-06.
- "The Swedish Act prohibiting certain doping substances (1991:1969)" (PDF). WADA. 1991. Archived from the original (PDF) on 2007-06-20. Retrieved 2007-05-06.
- Keeping, Juliana (27 December 2010). "Steroid abuse among law enforcement a problem nationwide". The Ann Arbor News. Retrieved 1 December 2013.
- "Anabolic Steroid Use and Abuse by Police Officers: Policy & Prevention". The Police Chief. June 2008. Retrieved 1 December 2013.
- Lockhart B (2010-03-01). "WWE steroid investigation: A controversy McMahon 'doesn't need'". Greenwich Time. Retrieved 2010-03-01.
- documents Archived December 24, 2010, at the Wayback Machine
- "Deposition details McMahon steroid testimony | News from southeastern Connecticut". The Day. 2007-12-13. Retrieved 2010-08-14.
- Assael, Shaun (2007-09-24). "'Raw Deal' busts labs across U.S., many supplied by China". ESPN The Magazine. Archived from the original on 14 October 2007. Retrieved 2007-09-24.
- Yesalis, C (2000). "Source of Anabolic Steroids". Anabolic Steroids in Sport and Exercise. Champaign, Ill.: Human Kinetics. ISBN 978-0-88011-786-9.
- Black, Terry (1996). "Does the Ban on Drugs in Sport Improve Societal Welfare?". Faculty of Business, Queensland University of Technology. Retrieved 2007-04-24.
- Pound RW (2006). "Organized Crime". Inside dope : how drugs are the biggest threat to sports, why you should care, and what can be done about them. Mississaug, Ontario: Wiley. p. 175. ISBN 978-0-470-83733-7.
- Kanayama G, Hudson JI, Pope HG (November 2008). "Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?". Drug Alcohol Depend. 98 (1–2): 1–12. doi:10.1016/j.drugalcdep.2008.05.004. PMC 2646607. PMID 18599224.
- "Steroids". National Institute on Drug Abuse. GDCADA. Archived from the original on 2007-09-11. Retrieved 2007-09-13.
- "The Drug Enforcement Administration's International Operations (Redacted)". Office of the Inspector General. USDOJ. February 2007. Retrieved 2014-01-02.
- Nieschlag E, Kumar N, Sitruk-Ware R (2013). "7α-methyl-19-nortestosterone (MENTR): the population council's contribution to research on male contraception and treatment of hypogonadism". Contraception. 87 (3): 288–95. doi:10.1016/j.contraception.2012.08.036. PMID 23063338.
- Gruber CJ, Wieser F, Gruber IM, Ferlitsch K, Gruber DM, Huber JC (December 2002). "Current concepts in aesthetic endocrinology". Gynecol. Endocrinol. 16 (6): 431–41. doi:10.1080/gye.16.6.431.441. PMID 12626029.
- Sam S (February 2015). "Adiposity and metabolic dysfunction in polycystic ovary syndrome". Horm Mol Biol Clin Investig. 21 (2): 107–16. doi:10.1515/hmbci-2015-0008. PMID 25781555.
- Schänzer W (1996). "Metabolism of anabolic androgenic steroids". Clin. Chem. 42 (7): 1001–20. PMID 8674183.
- Yesalis CE (2000). Anabolic Steroids in Sport and Exercise. Human Kinetics. ISBN 0-88011-786-9.
- Daniels RC (February 1, 2003). The Anabolic Steroid Handbook. RCD Books. p. 80. ISBN 0-9548227-0-6.
- Gallaway S (January 15, 1997). The Steroid Bible (3rd Sprl ed.). Belle Intl. p. 125. ISBN 1-890342-00-9.
- Llewellyn W (January 28, 2007). Anabolics 2007 : Anabolic Steroid Reference Manual (6th ed.). Body of Science. p. 988. ISBN 978-0-9679304-6-6.
- Roberts A, Clapp B (January 2006). Anabolic Steroids: Ultimate Research Guide. Anabolic Books, LLC. p. 394. ISBN 1-59975-100-3.
- Tygart TT (December 2009). "Steroids, the Media, and Youth". Prevention Researcher Integrated Research Services, Inc. SIRS Researcher. 16 (7–9).
- Eisenhauer L (Nov 7, 2005). "Do I Look OK?". St. Louis Post-Dispatch (St. Louis, MO). Retrieved 25 Oct 2010.
- Fragkaki AG, Angelis YS, Koupparis M, Tsantili-Kakoulidou A, Kokotos G, Georgakopoulos C (2009). "Structural characteristics of anabolic androgenic steroids contributing to binding to the androgen receptor and to their anabolic and androgenic activities. Applied modifications in the steroidal structure". Steroids. 74 (2): 172–97. doi:10.1016/j.steroids.2008.10.016. PMID 19028512.
- McRobb L, Handelsman DJ, Kazlauskas R, Wilkinson S, McLeod MD, Heather AK (2008). "Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay". J. Steroid Biochem. Mol. Biol. 110 (1–2): 39–47. doi:10.1016/j.jsbmb.2007.10.008. PMID 18395441.
- Media related to Anabolic-androgenic steroids at Wikimedia Commons